	ARTICLE	ARTICLE DATE	SENTENCE NUM	SENTENCE	IGNORANCE CATEGORIES	NUM IGNORANCE CATEGORIES	OBO ID (LABEL)
S137-PMC2749934	PMC2749934	9/2009	S137-PMC2749934	['normal arrows indicate no change in Gene Expression; dashed arrows indicate down regulation; bold arrows indicate up-regulation.10.1371/journal.pone.0007271.t004\n\ncaption (table-Wrap): table 4\nanalysis of Gene function associated with differentially Expressed Genes.metabolic areasymbolgene identification% δexpfunctioncarbohydrate and Glucose Metabolismgys2Glycogen Synthase54Stimulation of Glucose storagegbe1glucan 1,4Α branching enzyme−38impairment of Glycogen storagepgm1phosphoglucomutase−14increases Glycogenesis over Glycolysistpitriose Phosphate isomerase−28attenuation of Glycolysis and Energy Productiongcgrglucagon Receptor−15attenuation of Glycogenolysistrib3Tribbles Homolog 311impairment of Insulin/Igf Signaling at Akt[46]Ptprbprotein Tyrosine Phosphatase Receptor Type B25Impairment of Insulin/Igf Signaling at atk[47]Rbp1Retinol Binding Protein 163impairment of Insulin/Igf Signalling at pi3kinase[30]Igfbp2Insulin-Like Growth Factor Binding Protein 2114impaired igd binding to Receptorp49/strapsrf-dependent Transcription Regulation Associated Protein10Interference with Glut4 Biosynthesis and recycling[48]Trip3Thyroid Hormone Interactor Protein 3 (Trip3)6activator Of Nhf-4Α dependent EFFECTS on Glucose Metabolism[49]dhtkd1dehydrogenase e1 and transketolase30catalyses αketoglutarate→succinylcoa in tcafat and Lipid Metabolismcratcarnitine acyltransferase18increased Transport Of Acylcoa from Cytosol to Mitochondriontmhletrimethyllysine hydroxylase−12biosynthesis of Carnitinedgat2Diacylglycerol acyltransferase−12decreased Synthesis Of Triglyceridesfabp7Fatty Acid Binding Protein 740Increased Uptake and Intracellular Transport Of Fatty Acidsscapsrebp cleavage activating protein (Scap)20Increased Hepatic Lipid Synthesis[50]Igfbp2Igf binding protein 2114protection against obesity and Insulin resistance[51]Ptprbprotein Tyrosine Phosphatase Receptor Type B25Contributes to Hepatic leptin resistance[52]Stard5Steroidogenic Acute Regulatory Protein−12intracellular Cholesterol transportcyp4f4cytochrome P450−28involved in Cholesterol, Steroid and Leukotriene Synthesiscyp4F6Cytochrome P450−18involved in Cholesterol, Steroid and Leukotriene Synthesisatp8B1Atpase class ii type 8b16.5Phosphatidyl Serine and threonine transferasecideacell Death Inducing Dna Fragmentation Factor Α-like Effector−28shown to Regulate energy expenditure and Lipolysis[53],[54],[55],[56]Ebpphenyalkylamine Ca2+ antagonist (emopamil) binding protein20isomerase INVOLVED in the Conversion Of Lanosterol To Cholesterolamino Acid Metabolismgot2Glutamate/oxaloacetate transaminase−10aspartate aminotransferase in aa Catabolism and Malate shuttledhtkd1dehydrogenasee1 and transketolase Domain containing 1−302-ketoglutarate dehydrogenase activityhpd4-Hydroxyphenylpyruvate oxidase16participates in tyrosine Catabolismhaao3-hydroxyanthanillate dioxygenase−12participates in Tryptophan Catabolismprotein turnoverzfand2aarsenite inducible rna associated protein40adapts Proteosome to counteract stress-induced proteotoxicity[57]Tmprss6Transmembrane Serine Protease 6−15capn7calpain 7−15cpn2carboxypeptidase N83−58Capsn1Calpain Small Subunit 1−21fam108b1cgi67 serine protease−2.8serpinb6bserine(or Cysteine) Peptidase Inhibitor,Clade b, member 625cand1cullin associated/Neddylation dissociated 115involved in targeted Protein Proteosomal Degradation[58]dcun1d5defective in Cullin Neddylation1, Domain 5 (Dcn1)13involved in targeted Protein Proteosomal Degradation[59]Txndc12Thioredoxin Domain Containing 12 (Txndc12)20.6protein Refolding, Defense against oxidative stressubfd1ubiquitin Family Domain Containing 1 (Ubfd1)14involved in targeted protein Proteosomal Degradationeif4A1Translation Initiation Factor 4a120ribosomesrpl7aribosomal Protein L7A (Mitochondrial)24rps19ribosomal protein s1922rpl14ribosomal Protein L14 (Mitochondrial)20rps26ribosomal Protein S26 (Mitochondrial)19rp23aribosomal Protein 23A (Mitochondrial)19rpl27aribosomal Protein 27A (Mitochondrial)18rpl21ribosomal Proetin L21(Mitochondrial)17rpl31ribosomal protein l3117rpl39ribosomal protein l3915rpl6ribosomal protein l614rps17ribosomal Protein S17 (Mitochondrial)14rpl24ribosomal protetin l2414rpl13ribosomal Protein L13 (Mitochondrial)7npg1autoantigen npg116required for the maturation/Nuclear Export of Pre-Ribosomesbxdc1Brix Domain containing 111control of Ribosome Biogenesis[60]crlz1charged amino acid leucine zipper 126required for 18S Rrna Processingrrp15Ribosomal Protein Processing Homolog 15 (rrp15)17cebpzccaat/Enhancer Binding Protein zeta17.4ribosomal Rna Processing[35]Apoptosisdnase1L3Dnase 1-like 340fragments dna during Apoptosisppidpeptidyl prolyl isomerase d (Cyclophilin D)20anti-apoptotic.']	[('SUPERFICIAL_RELATIONSHIP', 1206), ('SUPERFICIAL_RELATIONSHIP', 2462)]	2	"[('GO_0010467', 'gene expression', 36, 'gene expression'), ('SO_0000704', 'gene', 36, 'gene'), ('PR_000017453', 'protein Wnt-9b', 178, 'WRAP'), ('SO_0000704', 'gene', 205, 'gene'), ('GO_0010467', 'gene expression', 250, 'expressed'), ('SO_0000704', 'gene', 260, 'genes'), ('CHEBI_17234', 'glucose', 336, 'Glucose'), ('GO_0006000', 'fructose metabolic process', 336, 'Glucose metabolismGys2glycogen'), ('PR_000015699', 'alpha-2,8-sialyltransferase 8E', 367, 'synthase54stimulation'), ('CHEBI_17234', 'glucose', 392, 'glucose'), ('PR_000008777', '17-beta-hydroxysteroid dehydrogenase 13', 418, '1,4α'), ('CHEBI_24384', 'glycogens', 456, 'glycogen'), ('GO_0006096', 'glycolytic process', 507, 'glycogenesis'), ('GO_0006096', 'glycolytic process', 525, 'glycolysisTpitriose'), ('CHEBI_18367', 'phosphate(3-)', 545, 'phosphate'), ('GO_0006096', 'glycolytic process', 582, 'glycolysis'), ('GO_0050798', 'activated T cell proliferation', 597, 'energy productionGcgrglucagon'), ('PR_000014368', 'RuvB-like 1', 627, 'receptor'), ('GO_0007402', 'ganglion mother cell fate determination', 653, 'glycogenolysisTrib3Tribbles'), ('SO_0000853', 'homologous_region', 681, 'homolog'), ('GO_0007631', 'feeding behavior', 706, 'insulin ...'), ('PR_000045358', 'insulin family protein', 706, 'insulin'), ('GO_0038028', 'insulin receptor signaling pathway via phosphatidylinositol 3-kinase', 714, 'IGF signaling'), ('PR_000003908', 'aflatoxin B1 aldehyde reductase member 2', 731, 'Akt'), ('PR_000001903', 'paired box protein PAX-5', 738, 'Ptprbprotein tyrosine phosphatase receptor type B25impairment'), ('GO_0007212', 'dopamine receptor signaling pathway', 803, 'insulin ... IGF signaling'), ('PR_000045358', 'insulin family protein', 803, 'insulin'), ('PR_000014333', 'R-spondin-4', 835, 'Rbp1Retinol binding protein'), ('GO_0007631', 'feeding behavior', 880, 'insulin ...'), ('PR_000045358', 'insulin family protein', 880, 'insulin'), ('GO_0038028', 'insulin receptor signaling pathway via phosphatidylinositol 3-kinase', 888, 'IGF signalling'), ('PR_000008895', 'alpha-L-iduronidase', 919, 'Igfbp2insulin-like growth factor binding protein'), ('PR_000014938', 'urea transporter 1', 996, 'receptorp49'), ('PR_000016478', 'tumor necrosis factor alpha-induced protein 8-like protein 2', 1027, 'transcription regulation associated protein10interference'), ('GO_0065007', 'biological regulation', 1041, 'regulation'), ('PR_000015065', 'solute carrier family 2, facilitated glucose transporter member 3', 1090, 'GLUT4'), ('GO_0009057', 'macromolecule catabolic process', 1096, 'biosynthesis'), ('PR_000016730', 'thymic stromal lymphopoietin', 1126, 'TRIP3thyroid hormone interactor protein 3'), ('CHEBI_33280', 'molecular messenger', 1139, 'hormone'), ('PR_000016670', 'Cdc42-interacting protein 4', 1169, 'TRIP3'), ('PR_000011598', 'outer dense fiber protein 2', 1186, 'of NHF-4α'), ('CHEBI_17234', 'glucose', 1217, 'glucose'), ('GO_0006006', 'glucose metabolic process', 1217, 'glucose metabolism'), ('CHEBI_18059', 'lipid', 1332, 'Lipid'), ('GO_0019284', 'L-methionine salvage from S-adenosylmethionine', 1332, 'Lipid MetabolismCratcarnitine'), ('GO_0006412', 'translation', 1389, 'transport of'), ('CHEBI_15347', 'acetone', 1402, 'acylCoA'), ('GO_0005829', 'cytosol', 1415, 'cytosol'), ('GO_0097427', 'microtubule bundle', 1426, 'mitochondrionTmhletrimethyllysine'), ('CHEBI_67111', 'N-acyl-1-deoxysphinganine', 1490, 'carnitineDgat2diacylglycerol'), ('GO_0019574', ""sucrose catabolic process via 3'-ketosucrose"", 1547, 'synthesis of triglyceridesFabp7fatty acid'), ('CHEBI_59649', 'amorolfine hydrochloride', 1560, 'triglyceridesFabp7fatty acid'), ('PR_000003909', 'aflatoxin B1 aldehyde reductase member 3', 1584, 'acid binding protein 740increased'), ('GO_0043052', 'thermotaxis', 1618, 'uptake ...'), ('GO_0005622', 'intracellular anatomical structure', 1629, 'intracellular'), ('GO_0006260', 'DNA replication', 1629, 'intracellular'), ('GO_0015904', 'tetracycline transmembrane transport', 1643, 'transport of fatty acidsScapSREBP'), ('CHEBI_77192', 'alpha-L-Fucp-(1->3)-[4d-beta-D-Galp-(1->4)]-beta-D-GlcpNAc-OMe', 1656, 'fatty acidsScapSREBP'), ('PR_000014450', 'histone deacetylase complex subunit SAP30L', 1706, 'Scap ... 20increased'), ('UBERON_0002107', 'liver', 1723, 'hepatic'), ('CHEBI_18059', 'lipid', 1731, 'lipid'), ('GO_0008610', 'lipid biosynthetic process', 1731, 'lipid synthesis'), ('PR_000008989', 'interleukin-1 family member 7', 1750, 'Igfbp2IGF'), ('PR_000045358', 'insulin family protein', 1811, 'insulin'), ('PR_000013346', 'gamma-secretase subunit PEN-2', 1833, 'Ptprbprotein tyrosine phosphatase receptor type B25contributes'), ('UBERON_0002107', 'liver', 1899, 'hepatic'), ('PR_000014450', 'histone deacetylase complex subunit SAP30L', 1928, 'Stard5steroidogenic acute regulatory protein'), ('GO_0007630', 'jump response', 1948, 'acute regulatory'), ('CHEBI_16113', 'cholesterol', 1989, 'cholesterol'), ('PR_000001900', 'neuropilin-1', 2027, 'P450'), ('CHEBI_16113', 'cholesterol', 2046, 'cholesterol'), ('CHEBI_35341', 'steroid', 2059, 'steroid'), ('GO_0036367', 'light adaption', 2071, 'leukotriene synthesisCyp4f6cytochrome'), ('PR_000001900', 'neuropilin-1', 2109, 'P450'), ('CHEBI_16113', 'cholesterol', 2128, 'cholesterol'), ('CHEBI_35341', 'steroid', 2141, 'steroid'), ('GO_0019697', 'L-xylitol catabolic process to xylulose 5-phosphate', 2153, 'leukotriene synthesisAtp8b1ATPase'), ('CHEBI_18323', 'anserine', 2206, '5phosphatidyl serine'), ('PR_000006629', 'docking protein 2', 2262, 'death inducing DNA fragmentation factor α'), ('GO_0006306', 'DNA methylation', 2277, 'DNA fragmentation'), ('CHEBI_35224', 'effector', 2309, 'effector'), ('GO_0065007', 'biological regulation', 2329, 'regulate'), ('GO_0016042', 'lipid catabolic process', 2361, 'lipolysis'), ('CHEBI_31582', 'Etilefrine hydrochloride (TN)', 2389, 'Ebpphenyalkylamine'), ('CHEBI_29108', 'calcium(2+)', 2408, 'Ca2+'), ('GO_0036214', 'contractile ring localization', 2478, 'conversion of ... to cholesterolAmino'), ('CHEBI_16521', 'lanosterol', 2492, 'lanosterol'), ('CHEBI_83378', '(S)-meptyldinocap', 2506, 'cholesterolAmino Acid'), ('GO_0019445', 'tyrosine catabolic process to fumarate', 2523, 'Acid MetabolismGot2glutamate'), ('GO_0009056', 'catabolic process', 2613, 'catabolism'), ('CHEBI_25147', 'mandelate', 2628, 'malate'), ('SO_0000417', 'polypeptide_domain', 2682, 'domain'), ('CHEBI_18035', 'diglyceride', 2747, 'hydroxyphenylpyruvate'), ('GO_0007623', 'circadian rhythm', 2803, 'catabolismHaao3'), ('GO_0006415', 'translational termination', 2869, 'tryptophan catabolismProtein'), ('GO_0005844', 'polysome', 2963, 'proteosome'), ('PR_000016833', 'tuftelin', 3021, 'Tmprss6transmembrane serine protease 6'), ('PR_000008440', 'heart- and neural crest derivatives-expressed protein 2', 3075, '7'), ('PR_000011040', 'nuclear receptor coactivator 1', 3100, 'N83'), ('PR_000011505', 'Numb-like protein', 3104, '58Capsn1calpain small subunit 1'), ('CHEBI_26834', 'sulfur-containing amino acid', 3190, 'cysteine'), ('PR_000014699', 'serpin B8', 3200, 'peptidase inhibitor'), ('CHEBI_35222', 'inhibitor', 3210, 'inhibitor'), ('PR_000005398', 'glutathione-specific gamma-glutamylcyclotransferase 1', 3220, 'clade'), ('GO_0007567', 'parturition', 3262, 'neddylation'), ('GO_0030167', 'proteoglycan catabolic process', 3310, 'protein proteosomal degradation'), ('GO_0005844', 'polysome', 3318, 'proteosomal'), ('PR_000005591', 'battenin', 3365, 'cullin'), ('GO_0017005', ""3'-tyrosyl-DNA phosphodiesterase activity"", 3372, 'neddylation1'), ('SO_0000417', 'polypeptide_domain', 3386, 'domain'), ('PR_000006317', 'mRNA-decapping enzyme 1A', 3396, 'DCN1'), ('GO_0030167', 'proteoglycan catabolic process', 3424, 'protein proteosomal degradation'), ('GO_0005844', 'polysome', 3432, 'proteosomal'), ('PR_000029840', 'tetratricopeptide repeat protein 7B', 3459, 'Txndc12Thioredoxin domain containing 12'), ('SO_0000417', 'polypeptide_domain', 3478, 'domain'), ('PR_000016642', 'E3 ubiquitin-protein ligase TRIM11', 3500, 'Txndc12'), ('GO_0065007', 'biological regulation', 3520, 'refolding'), ('GO_0006952', 'defense response', 3531, 'defense'), ('PR_000007319', 'fatty acid desaturase 3', 3578, 'family domain containing 1'), ('SO_0000417', 'polypeptide_domain', 3585, 'domain'), ('PR_000016973', 'ubiquitin-conjugating enzyme E2 E3', 3606, 'Ubfd1'), ('GO_0005844', 'polysome', 3643, 'proteosomal'), ('GO_0031143', 'pseudopodium', 3643, 'proteosomal degradationEif4a1translation initiation'), ('PR_000002050', 'interferon regulatory factor 8', 3684, 'initiation factor'), ('SO_0000365', 'integron', 3684, 'initiation'), ('PR_000007311', 'fatty acid-binding protein, heart', 3731, 'protein L7a'), ('GO_0005739', 'mitochondrion', 3744, 'mitochondrial'), ('PR_000014700', 'serpin B9', 3803, 'protein L14'), ('GO_0005739', 'mitochondrion', 3816, 'mitochondrial'), ('PR_000014700', 'serpin B9', 3847, 'protein S26'), ('GO_0005739', 'mitochondrion', 3860, 'mitochondrial'), ('PR_000010705', 'metallothionein-3', 3860, 'mitochondrial'), ('PR_000014700', 'serpin B9', 3891, 'protein 23a'), ('GO_0005739', 'mitochondrion', 3904, 'mitochondrial'), ('PR_000010705', 'metallothionein-3', 3904, 'mitochondrial'), ('PR_000014700', 'serpin B9', 3936, 'protein 27a'), ('GO_0005739', 'mitochondrion', 3949, 'mitochondrial'), ('PR_000010705', 'metallothionein-3', 3949, 'mitochondrial'), ('PR_000013109', 'protein phosphatase 1 regulatory subunit 12C', 3980, 'proetin L21'), ('GO_0005739', 'mitochondrion', 3992, 'mitochondrial'), ('PR_000014700', 'serpin B9', 4105, 'protein S17'), ('GO_0005739', 'mitochondrion', 4118, 'mitochondrial'), ('PR_000010705', 'metallothionein-3', 4118, 'mitochondrial'), ('PR_000017532', 'protein YIPF2', 4178, 'protein L13'), ('GO_0005739', 'mitochondrion', 4191, 'mitochondrial'), ('PR_000010705', 'metallothionein-3', 4191, 'mitochondrial'), ('GO_0005634', 'nucleus', 4256, 'nuclear'), ('GO_0051168', 'nuclear export', 4256, 'nuclear export'), ('GO_0030688', 'preribosome, small subunit precursor', 4274, 'pre-ribosomesBxdc1brix'), ('SO_0000010', 'protein_coding', 4274, 'pre-ribosomesBxdc1brix'), ('SO_0000417', 'polypeptide_domain', 4297, 'domain'), ('GO_0005840', 'ribosome', 4329, 'ribosome'), ('GO_0042254', 'ribosome biogenesis', 4329, 'ribosome biogenesis'), ('SO_0000407', 'cytosolic_18S_rRNA', 4407, '18s rRNA'), ('GO_0000725', 'recombinational repair', 4411, 'rRNA processingRrp15ribosomal'), ('GO_0016485', 'protein processing', 4441, 'protein processing'), ('PR_000012529', 'PDZK1-interacting protein 1', 4441, 'protein processing homolog 15'), ('SO_0000853', 'homologous_region', 4460, 'homolog'), ('PR_000006890', 'enhancer of mRNA-decapping protein 3', 4491, 'enhancer binding protein'), ('SO_0000165', 'enhancer', 4491, 'enhancer'), ('GO_0006396', 'RNA processing', 4534, 'RNA processing'), ('GO_0034356', 'NAD biosynthesis via nicotinamide riboside salvage pathway', 4552, 'ApoptosisDnase1l3DNAse'), ('PR_000003770', 'all-trans-retinol dehydrogenase [NAD(+)] ADH4', 4575, '1'), ('GO_0002502', 'peptide antigen assembly with MHC class I protein complex', 4606, 'apoptosisPpidpeptidyl'), ('PR_000006025', 'cathepsin D', 4648, 'Cyclophilin D')]"
S3-PMC4161853	PMC4161853	8/2014	S3-PMC4161853	['by mounting a rapid Antibody response against encapsulated bacteria, these cells are CRITICAL for the Defence against highly pathogenic microorganisms that do not elicit classical T Cell-dependent responses.']	[('IMPORTANT_CONSIDERATION', 85)]	1	[('GO_0042571', 'immunoglobulin complex, circulating', 20, 'antibody'), ('GO_0006952', 'defense response', 102, 'defence'), ('CL_0000084', 'T cell', 180, 'T cell')]
S31-PMC4090565	PMC4090565	6/2014	S31-PMC4090565	['crp is released by Adipose Tissue and is an IMPORTANT first line host Defense Molecule; it recognizes damaged cells and promotes their elimination by activating the complement system [13].']	[('IMPORTANT_CONSIDERATION', 44)]	1	[('UBERON_0001013', 'adipose tissue', 19, 'adipose tissue'), ('GO_0006952', 'defense response', 70, 'defense'), ('CHEBI_36357', 'polyatomic entity', 78, 'molecule')]
S97-PMC3976831	PMC3976831	3/2014	S97-PMC3976831	['Col1A1 , a known marker of fibrosis and Aging, HAS BEEN LINKED to alterations in oxidative and antioxidant Defense capacity in cells due to poor maternal nutrition [13].']	[('INCOMPLETE_EVIDENCE', 47), ('SUPERFICIAL_RELATIONSHIP', 56)]	2	[('PR_000003266', 'collagen type II alpha chain', 0, 'Col1a1'), ('GO_0007568', 'aging', 40, 'aging'), ('GO_0006952', 'defense response', 107, 'defense')]
S73-PMC4982007	PMC4982007	8/2016	S73-PMC4982007	['only 1 word or unintelligible utterances; moderate-children can produce 2-3 word phrases gross motor skills-ages and stages questionnaireuse of Folic Acid resulted in reduced risk of severe (or\u2009=\u20090.55) and moderate language delay (or\u2009=\u20090.80)no association between Folic Acid intake and delay in gross motor skillsconfounders adjusted for: maternal marital status, bmi, parity and education17 low33forns j; 2012 \u2003n \u2009=\u2009393\u2003age 11\xa0years\u2003population based prospective birth cohort; spainfolic Acid supplements with or without other Vitaminsdose and duration: no information.66.8\xa0% used Folic Acid\u2009+\u2009other supplementscontinuous performance test (attention function)omission error; commission errorhrt-mean response time (for correct hits)supplementation with Folic Acid reduced the incidence rate ratio (irr\u2009=\u20090.80) of omission errorsno ASSOCIATION with commission and hrtconfounders adjusted for: parity, pe, social class, miq, maternal mental health, ms, bwt, bf14 medium34julvez j; 2009 \u2003n \u2009=\u2009420\u2003age 4\xa0years\u2003population based prospective Birth cohort\u2003spainfolic Acid supplements with or without other Vitaminsdose and duration: no information34\xa0% used only Folic Acid24\xa0% used Folic Acid\u2009+\u2009other supplementsmccarthy scales of children’s abilitiesgeneral Cognitive scale and subscales (verbal, perceptive-performance, Memory, quantitative and motor) and executive function (verbal and perceptive-performance)use of maternal Folic Acid supplement was positively ASSOCIATED with verbal (general Cognitive) score (β\u2009=\u20093.98) and verbal (executive function (β\u2009=\u20093.97)), motor skills (β\u2009=\u20094.55)confounders adjusted for: the child’s sex, age, school season, area of residence, ga, bf, parity, maternal marital status, ms, use of Calcium and Iron supplements, me, pe and social class14 medium35holmes-siedle; 1992 \u2003n \u2009=\u200996 age 2-5 years\u2003uk\u2003prospective observationalperi-conceptional multivitamin containing Folic Acid (0.36\xa0mg) supplements daily with other Vitamins and Minerals (minimum 28\xa0days before Conception until the second missed Menstrual Period)denver developmental screening test (ddst) (language, motor and social skills)no significant difference in development score among supplemented group compared to general populationconfounders adjusted for: no information12 medium36campoy c; 2011 \u2003n \u2009=\u2009154\u2003age 6.5\xa0years\u2003double blind randomized controlled trial\u2003european centres (germany, spain and hungary)4 supplement (Milk based) groupsfish oil ( n \u2009=\u200937)5-Methyl Tetrahydrofolate-400\xa0μg ( n \u2009=\u200937)fish oil\u2009+\u20095-Methyl Tetrahydrofolate ( n \u2009=\u200935)placebo ( n \u2009=\u200945)daily supplementation from 20th week of Gestation until Deliveryplasma/Erythrocyte Folate concentrationsduring 2nd and 3rd trimester and at the time of delivery;no information about compliancekaufman assessment battery for children (kabc):sequential processing scalesimultaneous processing scalemental processing composite (mpc)no significant difference in Cognitive scores between supplement groupsno association of maternal Plasma or Erythrocyte Folate concentrations during Pregnancy and at the time of Delivery with Cognitive functionconfounders adjusted for: unadjusted19 low\nqs quality score, rb risk of bias, thcy total Homocysteine, hb haemoglobin, lmp last Menstrual Period, ffq Food frequency questionnaire, bmi body mass index, ga Gestational age, ma maternal age, bwt Birthweight, bf breast-feeding, ses socio-economic status, me maternal education, pe paternal education, miq maternal intelligence, he home environment, ms maternal smoking, mthfr Methylenetetrahydrofolate reductase\n\ncaption (table-wrap): table 5\n\nsummary of the studies examining associations of maternal Vitamin B12 status with offspring Cognitive functionauthor, year, sample size, age, country, study designnutrientcognitive functionresults after adjustment for confoundersqs and rb23wu btf; 2012 \u2003n \u2009=\u2009154\u2003age 18 months\u2003canada\u2003prospectiveplasma Vitamin B12 and holotranscobalamin concentrations assessed at 16 and 36\xa0weeks Gestation7.8\xa0% low B12 (<148 pmol/l)bayley scales of infant developmentreceptive language, expressive language, Cognitive skills, fine motor and gross motorno ASSOCIATION of b12 and holotranscobalamin with Cognitive functionconfounders adjusted for: the child’s sex, bf, ethnicity, ma, miq, maternal Fatty Acid level13 medium25bhate v; 2008 \u2003n \u2009=\u2009108\u2003age 9\xa0years\u2003india\u2003prospective community basedplasma Vitamin B12 concentrations assessed at 28\xa0weeks Gestationb12 status 2 groupslowest <77 pmol/lhighest >224 pmol/lraven’s coloured progressive matrices-Intelligencevisual recognitioncolour trial test-sustained attention and executive functiondigit-span test-Short-Term or Working Memorychildren in group 1 performed slowly in sustained attention (182\xa0seconds vs 159) and Short-Term Memory (2.6 digits vs 2.9)no association with other testsconfounders adjusted for: the child’s sex, age, education, weight and Head circumference, b12 level, ses, education of the head of the family14 medium26veena sr; 2010 \u2003n \u2009=\u2009536\u2003age 9-10 years\u2003india\u2003prospective Birth cohortplasma Vitamin-B12 concentrations assessed at 30\u2009±\u20092\xa0weeks Gestationlow B12-(B12\u2009<\u2009150 pmol/l)-42\xa0%kauffman assessment battery for children-ii-Learning, Long-Term Retrieval, Short-Term Memory and reasoningwechsler intelligence scale for children-iii-attention and concentrationkoh’s block design-visuo-spatial abilityverbal fluencyno ASSOCIATION between B12 concentrations and Cognitive functionno difference in mean score between children of mothers with low and normal b12 statusconfounders adjusted for: the child’s sex, ga, weight and Head circumference at Birth, parity, ma, maternal bmi, me, pe, ses, religion, rural/urban residence, the child’s current age, education, Head circumference, bmi and b12 concentrations16 medium28del rio garcia; 2009 \u2003n \u2009=\u2009253\u2003age infancy (1- 12\xa0months)\u2003mexico\u2003prospective Birth cohortdaily dietary intake of Vitamin B12 (first trimester ffq)deficient daily dietary Intake(b 12\u2009<\u20092.0\xa0μg/day) – 21.3\xa0%bayley scales of infant development -ii (mental development index(mdi) and Psychomotor Development index (pdi))b12 Intake deficiency-↓Mental Development (β\u2009=\u2009-1.6 points)confounders adjusted for: bwt, bf, current age, energy intake at age 6\xa0months, maternal bmi, Pregnancy hypertension, me, he and mthfr 1298a\u2009>\u2009c genotype16 medium29villamor e; 2012 \u2003n \u2009=\u20091210\u2003age 3\xa0years\u2003usa\u2003prospective pre-Birth cohortaverage daily intake of Vitamin B12 - 1st and 2nd trimester(ffq\u2009+\u2009supplements)peri-Conceptional b12 Intake from supplements(lmp - 4wks Gestation)peabody picture vocabulary test-receptive languagewide range assessment of Visual motor abilities-Visual-motor; Visual-spatial and fine motor↑ B12 Intake (2.6\xa0μg/day) during 2nd trimester (not 1st trimester) -↓ (0.4 points) Receptive languageno association of peri-Conceptional b12 Intake with Cognitive functionconfounders adjusted for: ma, parity, ethnicity, ms, pre-Pregnancy bmi, me, pe, miq, energy, fish and iron intake, income, the child’s sex and english as primary language15 medium30boeke c; 2013 \u2003n \u2009=\u2009895\u2003age 7\xa0years\u2003usa\u2003prospective pre-Birth cohortaverage daily Intake of b12 at 1st and 2nd Trimester (ffq\u2009+\u2009supplements)peabody picture vocabulary test-receptive languagewide range assessment of Memory and Learning-ii edition, design and picture Memory subtests: visuo-spatial Memorykaufman brief Intelligence test-ii editionverbal and non-verbal intelligenceno association of b12 intake with Cognitive functionconfounders adjusted for: ma, parity, ethnicity, ms, me, pe, miq, he, intake of energy, fish and other Methyl donors, the child’s sex and current age16 medium37bonilla c; 2012 \u2003n \u2009=\u20096259\u2003age 8\xa0years\u2003uk\u2003population based prospective Birth cohortdaily dietary Vitamin B12 intake.']	[('SUPERFICIAL_RELATIONSHIP', 831), ('SUPERFICIAL_RELATIONSHIP', 1457), ('SUPERFICIAL_RELATIONSHIP', 4125), ('SUPERFICIAL_RELATIONSHIP', 5362)]	4	[('CHEBI_30751', 'formic acid', 144, 'folic acid'), ('CHEBI_30751', 'formic acid', 264, 'folic acid'), ('CHEBI_37527', 'acid', 488, 'acid'), ('CHEBI_10124', 'zolmitriptan', 527, 'vitaminsDose'), ('CHEBI_30751', 'formic acid', 581, 'folic acid'), ('CHEBI_30751', 'formic acid', 753, 'folic acid'), ('GO_0007567', 'parturition', 1035, 'birth'), ('CHEBI_37527', 'acid', 1059, 'acid'), ('CHEBI_10124', 'zolmitriptan', 1098, 'vitaminsDose'), ('CHEBI_73677', '(S)-alpha-hydroxyglutaric acid-gamma-lactone', 1154, 'folic acid24'), ('CHEBI_30751', 'formic acid', 1174, 'folic acid'), ('GO_0050890', 'cognition', 1251, 'cognitive'), ('GO_0007613', 'memory', 1314, 'memory'), ('CHEBI_30751', 'formic acid', 1420, 'folic acid'), ('GO_0050890', 'cognition', 1489, 'cognitive'), ('CHEBI_22313', 'alkaline earth metal atom', 1718, 'calcium'), ('CHEBI_24870', 'ion', 1730, 'iron'), ('CHEBI_30751', 'formic acid', 1895, 'folic acid'), ('CHEBI_33277', 'gamma-tocotrienol', 1945, 'vitamins'), ('CHEBI_46751', 'quinolizidine', 1958, 'minerals'), ('GO_0007620', 'copulation', 1991, 'conception'), ('GO_0007613', 'memory', 2026, 'menstrual'), ('UBERON_0006505', 'palmar interosseous muscle of manus', 2026, 'menstrual period'), ('UBERON_0001913', 'milk', 2413, 'milk'), ('CHEBI_20612', '5-methyltetrahydrofolate', 2450, '5-methyl tetrahydrofolate'), ('CHEBI_44700', 'L-ornithyl group', 2504, '5-methyl'), ('CHEBI_67016', 'tetrahydrofolate', 2513, 'tetrahydrofolate'), ('GO_0007565', 'female pregnancy', 2598, 'gestation'), ('GO_0006952', 'defense response', 2614, 'deliveryPlasma'), ('CL_0000232', 'erythrocyte', 2629, 'erythrocyte'), ('CHEBI_30863', '5-azaorotic acid', 2641, 'folate'), ('GO_0050890', 'cognition', 2915, 'cognitive'), ('UBERON_0001969', 'blood plasma', 2984, 'plasma'), ('CL_0000232', 'erythrocyte', 2994, 'erythrocyte'), ('CHEBI_30863', '5-azaorotic acid', 3006, 'folate'), ('GO_0007565', 'female pregnancy', 3035, 'pregnancy'), ('GO_0007567', 'parturition', 3064, 'delivery'), ('GO_0050890', 'cognition', 3078, 'cognitive'), ('CHEBI_17088', 'monoacyl-sn-glycerol 3-phosphate', 3185, 'homocysteine'), ('GO_0007613', 'memory', 3224, 'menstrual'), ('UBERON_0006505', 'palmar interosseous muscle of manus', 3224, 'menstrual period'), ('CHEBI_33290', 'food', 3246, 'food'), ('GO_0007565', 'female pregnancy', 3300, 'gestational'), ('GO_0007596', 'blood coagulation', 3338, 'birthweight'), ('CHEBI_38725', 'mevinphos', 3518, 'methylenetetrahydrofolate'), ('CHEBI_33279', 'vitamin D5', 3644, 'vitamin B12'), ('PR_000004481', 'V-type proton ATPase subunit B, kidney isoform', 3644, 'vitamin B12'), ('GO_0050890', 'cognition', 3678, 'cognitive'), ('CHEBI_33279', 'vitamin D5', 3888, 'vitamin B12'), ('PR_000004481', 'V-type proton ATPase subunit B, kidney isoform', 3888, 'vitamin B12'), ('GO_0007565', 'female pregnancy', 3966, 'gestation7'), ('CHEBI_27778', 'abequose', 3985, 'B12'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 3985, 'B12'), ('GO_0050890', 'cognition', 4078, 'cognitive'), ('GO_0050890', 'cognition', 4172, 'cognitive'), ('CHEBI_35366', 'fatty acid', 4266, 'fatty acid'), ('CHEBI_28334', 'malonamoyl-CoA', 4369, 'Vitamin B12'), ('PR_000017279', 'testis-specific basic protein Y 1', 4369, 'Vitamin B12'), ('GO_0007565', 'female pregnancy', 4417, 'gestationB12'), ('GO_0038028', 'insulin receptor signaling pathway via phosphatidylinositol 3-kinase', 4519, 'IntelligenceVisual'), ('GO_0048574', 'long-day photoperiodism, flowering', 4625, 'short-term ... working memoryChildren'), ('GO_0007608', 'sensory perception of smell', 4738, 'short-term memory'), ('UBERON_0000033', 'head', 4876, 'head'), ('GO_0007567', 'parturition', 5016, 'birth'), ('CHEBI_83556', 'N-terminal L-leucyl-L-alpha-amino acid(1+) residue', 5035, 'vitamin-B12'), ('PR_000017260', 'tubulinyl-Tyr carboxypeptidase 1', 5035, 'vitamin-B12'), ('GO_0007565', 'female pregnancy', 5087, 'gestationLow'), ('CHEBI_27778', 'abequose', 5100, 'B12'), ('CHEBI_27778', 'abequose', 5105, 'B12'), ('GO_0007612', 'learning', 5171, 'Learning'), ('GO_0048867', 'stem cell fate determination', 5181, 'long-term retrieval'), ('GO_0007608', 'sensory perception of smell', 5202, 'short-term memory'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 5382, 'B12'), ('GO_0050890', 'cognition', 5405, 'cognitive'), ('UBERON_0000033', 'head', 5567, 'head'), ('GO_0007567', 'parturition', 5589, 'birth'), ('UBERON_0000033', 'head', 5704, 'head'), ('GO_0007567', 'parturition', 5838, 'birth'), ('CHEBI_33279', 'vitamin D5', 5874, 'vitamin B12'), ('PR_000004481', 'V-type proton ATPase subunit B, kidney isoform', 5874, 'vitamin B12'), ('GO_0007631', 'feeding behavior', 5931, 'intake'), ('GO_0048339', 'paraxial mesoderm development', 6040, 'Psychomotor Development'), ('GO_0007631', 'feeding behavior', 6080, 'intake'), ('GO_0030901', 'midbrain development', 6099, 'mental development'), ('GO_0007565', 'female pregnancy', 6228, 'pregnancy'), ('GO_0007567', 'parturition', 6358, 'birth'), ('CHEBI_33279', 'vitamin D5', 6394, 'vitamin B12'), ('PR_000004481', 'V-type proton ATPase subunit B, kidney isoform', 6394, 'vitamin B12'), ('GO_0007620', 'copulation', 6453, 'conceptional'), ('GO_0007631', 'feeding behavior', 6470, 'intake'), ('GO_0007565', 'female pregnancy', 6505, 'gestation'), ('GO_0007601', 'visual perception', 6590, 'Visual'), ('GO_0007601', 'visual perception', 6613, 'visual'), ('GO_0007601', 'visual perception', 6627, 'visual'), ('CHEBI_27778', 'abequose', 6658, 'B12'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 6658, 'B12'), ('GO_0007631', 'feeding behavior', 6662, 'intake'), ('GO_0000003', 'reproduction', 6739, 'receptive'), ('GO_0007620', 'copulation', 6780, 'conceptional'), ('GO_0007631', 'feeding behavior', 6797, 'intake'), ('GO_0050890', 'cognition', 6809, 'cognitive'), ('GO_0007565', 'female pregnancy', 6884, 'pregnancy'), ('GO_0007567', 'parturition', 7064, 'birth'), ('GO_0007631', 'feeding behavior', 7090, 'intake'), ('GO_0009294', 'DNA mediated transformation', 7119, 'trimester'), ('GO_0007613', 'memory', 7223, 'Memory'), ('GO_0007612', 'learning', 7234, 'Learning'), ('GO_0007613', 'memory', 7274, 'Memory'), ('GO_0007613', 'memory', 7305, 'memoryKaufman'), ('GO_0036155', 'acylglycerol acyl-chain remodeling', 7325, 'Intelligence'), ('GO_0050890', 'cognition', 7421, 'cognitive'), ('CHEBI_32875', 'methyl group', 7542, 'methyl'), ('GO_0007567', 'parturition', 7670, 'birth'), ('CHEBI_33279', 'vitamin D5', 7696, 'vitamin B12'), ('PR_000004481', 'V-type proton ATPase subunit B, kidney isoform', 7696, 'vitamin B12')]
S72-PMC4857870	PMC4857870	5/2016	S72-PMC4857870	['these include signs of anxious behavior, Cognitive difficulties and stereotypical, repetitious behavior.126)moreover, the production of Short-Chain Fatty Acids (e.g., Butyric Acid) by microbial activity on dietary fiber MAY play a key ROLE in the Development and function Of Microglia.127)Short Chain Fatty Acids derived from the Colon MAY BE able to pass the Blood-Brain barrier and INFLUENCE transcellular Neurotransmitter cycles.128)SINCE normal-functioning Microglia are ESSENTIAL in striking the optimal balance between host Defense and Synaptic plasticity (over-activation HAS BEEN LINKED to Neuroinflammation), the ways in which environmental factors INFLUENCE both Gut microbiota and neurochemistry are PROBABLY not YET FULLY REALIZED.']	[('INCOMPLETE_EVIDENCE', 220), ('SUPERFICIAL_RELATIONSHIP', 235), ('INCOMPLETE_EVIDENCE', 336), ('SUPERFICIAL_RELATIONSHIP', 384), ('PROBABLE_UNDERSTANDING', 436), ('IMPORTANT_CONSIDERATION', 475), ('INCOMPLETE_EVIDENCE', 579), ('SUPERFICIAL_RELATIONSHIP', 588), ('SUPERFICIAL_RELATIONSHIP', 658), ('PROBABLE_UNDERSTANDING', 711), ('INCOMPLETE_EVIDENCE', 724)]	11	[('GO_0050890', 'cognition', 41, 'cognitive'), ('CHEBI_26666', 'short-chain fatty acid', 136, 'short-chain fatty acids'), ('CHEBI_30772', 'butyric acid', 167, 'butyric acid'), ('GO_0001889', 'liver development', 247, 'development ... of microglia'), ('CL_0000129', 'microglial cell', 275, 'microglia'), ('CHEBI_87165', 'C50 carotenoid', 289, 'Short chain fatty acids'), ('UBERON_0001155', 'colon', 330, 'colon'), ('UBERON_0000178', 'blood', 360, 'blood'), ('UBERON_0000955', 'brain', 366, 'brain'), ('CHEBI_25512', 'neurotransmitter', 408, 'neurotransmitter'), ('CL_0000129', 'microglial cell', 461, 'microglia'), ('GO_0006952', 'defense response', 530, 'defense'), ('GO_0045202', 'synapse', 542, 'synaptic'), ('GO_0007009', 'plasma membrane organization', 598, 'neuroinflammation'), ('UBERON_0001555', 'digestive tract', 673, 'gut')]
S74-PMC4214174	PMC4214174	9/2014	S74-PMC4214174	['it is LIKELY that this marked divergence from the normal Immune state of the Placenta is ASSOCIATED with significant epigenetic changes (eg, hypomethylation of inflammatory cytokine Genes), AS maternal dietary extremes (ie, protein restriction) CAN cause the altered Expression of Genes INVOLVED in epigenetic modifications.127moreover, due to the dual ROLE of innate Immune Molecules in host Defense and developmental processes (as discussed above), the creation of an inflammatory milieu in utero CAN have SIGNIFICANT consequences for later-Life Brain function and behavior.']	[('PROBABLE_UNDERSTANDING', 6), ('SUPERFICIAL_RELATIONSHIP', 89), ('PROBABLE_UNDERSTANDING', 190), ('INCOMPLETE_EVIDENCE', 245), ('SUPERFICIAL_RELATIONSHIP', 287), ('SUPERFICIAL_RELATIONSHIP', 353), ('INCOMPLETE_EVIDENCE', 499), ('IMPORTANT_CONSIDERATION', 508)]	8	[('UBERON_0002405', 'immune system', 57, 'immune'), ('UBERON_0001987', 'placenta', 77, 'placenta'), ('SO_0000704', 'gene', 182, 'genes'), ('GO_0010467', 'gene expression', 267, 'expression'), ('SO_0000704', 'gene', 281, 'genes'), ('UBERON_0002405', 'immune system', 368, 'immune'), ('CHEBI_36357', 'polyatomic entity', 375, 'molecules'), ('GO_0006952', 'defense response', 393, 'defense'), ('UBERON_0000104', 'life cycle', 543, 'life'), ('UBERON_0000955', 'brain', 548, 'brain')]
S78-PMC4214174	PMC4214174	9/2014	S78-PMC4214174	['the enzyme indoleamine 2,3-Diox-Ygenase (ido), which causes tryptophan degradation, is Expressed in the normal Placenta, but is upregulated by high levels of proinflammatory cytokines, resulting in decreased Serotonin Synthesis and a POTENTIALLY damaging by-product, Quinolinic Acid, which is a helpful Defense against a pathogen, BUT also a potent nmda receptor Agonist that is capable of causing excitotoxicity and oxidative stress in the Brain.129for example, maternal endotoxin exposure decreased Serotonin Synthesis, increased Cell Death, and diminished serotonergic innervation of the Somatosensory Cortex in the Brains of newborn Rabbits.130THOUGH YET to be tested, IT IS POSSIBLE that maternal high-fat diet disrupts the DELICATE balance between the cytokine - and Serotonin-producing capabilities of the Placenta that is CRITICAL for normal Brain Development, which, especially in light of later-Life alterations in Serotonin receptor Expression,12may underlie the OBSERVED ASSOCIATION with offspring mood disorders and Cognitive alterations.']	[('INCOMPLETE_EVIDENCE', 234), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 331), ('ANOMALY_CURIOUS_FINDING', 645), ('ANOMALY_CURIOUS_FINDING', 645), ('ANOMALY_CURIOUS_FINDING', 655), ('INCOMPLETE_EVIDENCE', 673), ('IMPORTANT_CONSIDERATION', 729), ('IMPORTANT_CONSIDERATION', 830), ('INCOMPLETE_EVIDENCE', 974), ('SUPERFICIAL_RELATIONSHIP', 983)]	10	[('CHEBI_74156', '3-amino-4,7-dihydroxycoumarin(1-)', 23, '2,3-diox-ygenase'), ('GO_0010467', 'gene expression', 87, 'expressed'), ('UBERON_0001987', 'placenta', 111, 'placenta'), ('CHEBI_28790', 'serotonin', 208, 'serotonin'), ('GO_0042427', 'serotonin biosynthetic process', 208, 'serotonin synthesis'), ('CHEBI_16675', 'quinolinic acid', 267, 'quinolinic acid'), ('GO_0006952', 'defense response', 303, 'defense'), ('CHEBI_85384', 'GABA reuptake inhibitor', 363, 'agonist'), ('UBERON_0000955', 'brain', 441, 'brain'), ('CHEBI_28790', 'serotonin', 501, 'serotonin'), ('GO_0009057', 'macromolecule catabolic process', 511, 'synthesis'), ('GO_0008219', 'cell death', 532, 'cell death'), ('UBERON_0008930', 'somatosensory cortex', 591, 'somatosensory cortex'), ('UBERON_0000955', 'brain', 619, 'brains'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 637, 'rabbits'), ('CHEBI_28790', 'serotonin', 773, 'serotonin'), ('UBERON_0001987', 'placenta', 813, 'placenta'), ('GO_0007420', 'brain development', 850, 'brain development'), ('UBERON_0000955', 'brain', 850, 'brain'), ('UBERON_0000104', 'life cycle', 905, 'life'), ('CHEBI_28790', 'serotonin', 925, 'serotonin'), ('GO_0010467', 'gene expression', 944, 'expression'), ('GO_0050890', 'cognition', 1029, 'cognitive')]
S272-PMC4931906	PMC4931906	5/2016	S272-PMC4931906	['ALTHOUGH these EFFECTS are ATTRIBUTED to Progesterone’s INTERACTIONS with Brain reward Circuitry, they MIGHT INSTEAD be due to Progesterone’s activation of Toxin Defense mechanisms, as EVIDENCED by Progesterone’s up-regulation of p450 Toxin Metabolizing enzymes.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('SUPERFICIAL_RELATIONSHIP', 15), ('SUPERFICIAL_RELATIONSHIP', 27), ('SUPERFICIAL_RELATIONSHIP', 56), ('INCOMPLETE_EVIDENCE', 103), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 109), ('INCOMPLETE_EVIDENCE', 185)]	8	[('CHEBI_17026', 'progesterone', 41, 'progesterone'), ('UBERON_0000955', 'brain', 74, 'brain'), ('UBERON_0024914', 'circuit part of central nervous system', 87, 'circuitry'), ('CHEBI_17026', 'progesterone', 127, 'progesterone'), ('CHEBI_27026', 'toxin', 156, 'toxin'), ('GO_0006952', 'defense response', 162, 'defense'), ('CHEBI_17026', 'progesterone', 198, 'progesterone'), ('CHEBI_27026', 'toxin', 235, 'toxin'), ('GO_0008152', 'metabolic process', 241, 'metabolizing')]
S123-PMC5133065	PMC5133065	10/2016	S123-PMC5133065	['ON THE BASIS OF the KNOWN ROLE of Tgf-Β1 on the level of siga [16], that serves as a first line of Defense in Gut Mucosal Immunity [17], IT IS POSSIBLE to HYPOTHESIZE that the increase of Tgf-Β1 levels in Breast Milk, induced by this high dose Probiotic preparation, may be RESPONSIBLE for the significantly higher siga levels FOUND in Stools of infants whose mothers took the Probiotic product at t30 (figure 3b).']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 20), ('SUPERFICIAL_RELATIONSHIP', 26), ('INCOMPLETE_EVIDENCE', 137), ('INCOMPLETE_EVIDENCE', 155), ('PROBABLE_UNDERSTANDING', 274), ('INCOMPLETE_EVIDENCE', 327)]	7	[('PR_000000183', 'TGF-beta 2', 34, 'TGF-β1'), ('GO_0006952', 'defense response', 99, 'defense'), ('UBERON_0007142', 'left internal carotid artery', 110, 'gut mucosal'), ('GO_0007566', 'embryo implantation', 122, 'immunity'), ('PR_000000183', 'TGF-beta 2', 188, 'TGF-β1'), ('UBERON_0000310', 'breast', 205, 'breast'), ('UBERON_0001913', 'milk', 212, 'milk'), ('CHEBI_73033', 'pterocarpan', 244, 'probiotic'), ('UBERON_0000945', 'stomach', 336, 'stools'), ('CHEBI_73033', 'pterocarpan', 377, 'probiotic')]
S98-PMC5054480	PMC5054480	9/2016	S98-PMC5054480	['caption (table-wrap): table 3\n\nsummary of the literature on fibroma‐associated hypercalcemia in Pregnancytarnawa et al.20rahil et al.21maternal age (years)3236gestational age at discovery29 weeksfirst month of Pregnancyclinical presentationlethargy, nausea, vomiting, Abdominal painnausea, vomiting, Abdominal pain, weight lossclinical course33 5/7 weeks\naspiration pneumonia, intubation\nadmission to Intensive Care unit\nspontaneous labor, Vaginal Delivery\nPostmyomectomy hemorrhage34 weeks\npprom, emergency cesarean section\npostoperative septic shock and hemorrhage\nslight Neurological impairment secondary to diffuse ischemic changes and hypoxic insultnewborniugr, no Postnatal COMPLICATIONSNO COMPLICATIONSSURGERYMYOMECTOMY immediately after Deliverymyomectomy with cesarean sectionmaximal Ca level (mmol/l)5.2 (nr 2.1–2.63)4.8 (nr 2.1–2.6)Pth (pmol/l)undetectable0.3 (nr 1.6–6.9)Pthrp (pmol/l)22 (nr < 2)n/atreatmenthydration, Furosemide, Pamidronate 15 h after Delivery, Dialysiscalcitonin, dialysisfibroma characteristics23 cm in diameter, benign pedunculatedhistological proof of Pthrp Expression30 cm in diameter, calcifications, benign\nca, calcium; iugr, Intrauterine growth restriction; n/a, not available; nr, normal range; pprom, premature preterm rupture of membranes; pth, Parathyroid hormone; Pthrp, Parathyroid Hormone‐Related Protein.john wiley & sons, ltd\n\ncaption (table-wrap): table 4\n\nsummary of the literature on fibroma‐ASSOCIATED hypercalcemia in nonpregnant womenbilici et al.22dagdelen et al.23herring et al.24garcha et al.25age (years)45484979clinical presentationanorexia, nausea, vomiting, constipationuncontrolled type 2 diabetes mellitus, Inguinal pain, menometrorrhagialethargyaltered mental status, falls, acute Renal failurediscovery of fibromagynecologic examination + ct scanct scanultrasound + ct scanct scansurgerytah‐bsotah‐bsotah‐bsotah‐bsomaximal Ca level (mmol/l)4 (nr 2.1–2.63)3 (nr n/a)3.37 (nr 2.1–2.6)4.25 (nr n/a)pth (pmol/l)undetectableundetectable0.3 (nr 0.7–5.7)1.4 (nr 1.6–6.9)Pthrp (pmol/l)1.4 (nr < 1.3)2.5 (nr < 1.3)4.6 (nr < 1.8)40 (nr 14–27)treatmenthydration, Calcitonin, Furosemide, Pamidronatehydration, Furosemidezoledronic Acidhydration, Furosemidefibroma characteristics6 cm, intramural6.9 cm, Intramural7.5 cm, UNCERTAIN malignant potential, histological proof of Pthrp Expressionsmall and multiple\nca, calcium; n/a, not available; nr, normal range; pth, Parathyroid hormone; Pthrp, Parathyroid Hormone‐Related Protein; tah‐bso, total Abdominal hysterectomy and bilateral Salpingo‐Oophorectomy.john wiley & sons, ltd\n\ntreatment of hypercalcemia in Pregnancy\nmost of the nonpharmacologic and pharmacologic approaches used in nonpregnant women apply to Pregnant women as well.']	[('PROBLEM_COMPLICATION', 680), ('PROBLEM_COMPLICATION', 696), ('SUPERFICIAL_RELATIONSHIP', 1443), ('FULL_UNKNOWN', 2274)]	4	[('GO_0006412', 'translation', 96, 'pregnancyTarnawa'), ('GO_0006626', 'protein targeting to mitochondrion', 210, 'pregnancyClinical'), ('UBERON_0000916', 'abdomen', 268, 'abdominal'), ('UBERON_0000916', 'abdomen', 300, 'abdominal'), ('UBERON_0001007', 'digestive system', 401, 'intensive care'), ('UBERON_0001987', 'placenta', 440, 'vaginal'), ('GO_0007567', 'parturition', 448, 'delivery'), ('GO_0007602', 'phototransduction', 457, 'Postmyomectomy'), ('UBERON_0001016', 'nervous system', 574, 'neurological'), ('GO_0007567', 'parturition', 670, 'postnatal'), ('GO_0006952', 'defense response', 745, 'deliveryMyomectomy'), ('CHEBI_32588', 'potassium chloride', 793, 'Ca'), ('CHEBI_8102', 'phenylmethanesulfonyl fluoride', 843, 'PTH'), ('PR_000013439', 'prostate tumor-overexpressed gene 1 protein', 883, 'PTHrP'), ('CHEBI_47426', 'furosemide', 931, 'furosemide'), ('CHEBI_7903', 'pamidronate', 943, 'pamidronate'), ('GO_0007567', 'parturition', 966, 'delivery'), ('GO_0019651', 'citrate catabolic process to diacetyl', 976, 'dialysisCalcitonin'), ('PR_000013439', 'prostate tumor-overexpressed gene 1 protein', 1087, 'PTHrP'), ('GO_0010467', 'gene expression', 1093, 'expression30'), ('UBERON_0022293', 'reproductive gland secretion', 1164, 'intrauterine'), ('UBERON_0001132', 'parathyroid gland', 1287, 'parathyroid'), ('PR_000013439', 'prostate tumor-overexpressed gene 1 protein', 1308, 'PTHrP'), ('PR_000014709', 'neuroserpin', 1315, 'parathyroid hormone‐related protein'), ('UBERON_0001132', 'parathyroid gland', 1315, 'parathyroid'), ('UBERON_0008337', 'inguinal part of abdomen', 1670, 'inguinal'), ('UBERON_0002113', 'kidney', 1745, 'renal'), ('CHEBI_32588', 'potassium chloride', 1888, 'Ca'), ('PR_000013439', 'prostate tumor-overexpressed gene 1 protein', 2028, 'PTHrP'), ('CHEBI_41402', 'carboxymethyl group', 2117, 'calcitonin'), ('CHEBI_47426', 'furosemide', 2129, 'furosemide'), ('CHEBI_58955', 'branched-chain fatty acid anion', 2141, 'pamidronateHydration'), ('CHEBI_52825', 'DY-676(1-)', 2163, 'furosemideZoledronic acidHydration'), ('CHEBI_82701', 'idelalisib', 2199, 'furosemideFibroma'), ('UBERON_2002160', 'ural centrum 3', 2256, 'intramural7'), ('PR_000013439', 'prostate tumor-overexpressed gene 1 protein', 2327, 'PTHrP'), ('GO_0019149', '3-chloro-D-alanine dehydrochlorinase activity', 2333, 'expressionSmall'), ('UBERON_0001132', 'parathyroid gland', 2418, 'parathyroid'), ('PR_000013439', 'prostate tumor-overexpressed gene 1 protein', 2439, 'PTHrP'), ('PR_000014709', 'neuroserpin', 2446, 'parathyroid hormone‐related protein'), ('UBERON_0001132', 'parathyroid gland', 2446, 'parathyroid'), ('UBERON_0000916', 'abdomen', 2498, 'abdominal'), ('UBERON_0001155', 'colon', 2535, 'salpingo'), ('UBERON_0001000', 'vas deferens', 2544, 'oophorectomy'), ('GO_0007565', 'female pregnancy', 2611, 'pregnancy'), ('GO_0007565', 'female pregnancy', 2714, 'pregnant')]
S13-PMC1252725	PMC1252725	10/2005	S13-PMC1252725	['infusion treatment is also used in Pregnant women particularly for prolonging Pregnancy in women AT RISK for Preterm Delivery6, with extreme SEVERE nausea-vomiting (the so-called Hyperemesis gravidarum)7,8and after surgery large volumes of hypotonic Fluid are GENERALLY given to Pregnant women9,10.']	[('IMPORTANT_CONSIDERATION', 97), ('IMPORTANT_CONSIDERATION', 141), ('PROBABLE_UNDERSTANDING', 260)]	3	[('GO_0007565', 'female pregnancy', 35, 'pregnant'), ('GO_0007565', 'female pregnancy', 78, 'pregnancy'), ('GO_0007565', 'female pregnancy', 109, 'preterm'), ('GO_0006952', 'defense response', 117, 'delivery6'), ('GO_0030097', 'hemopoiesis', 179, 'hyperemesis'), ('UBERON_0006314', 'bodily fluid', 250, 'fluid'), ('GO_0007565', 'female pregnancy', 279, 'pregnant')]
S23-PMC2098747	PMC2098747	10/2007	S23-PMC2098747	['caption (table-wrap): table 1\n\nhypercoaguability profilefibrinogenfactor viiifactor ixfactor xianti-Phosphatidyl serine Iggβ2 glycoproteinanti-cardiolipin Igm and Igglupus Anticoagulantplasminogeneuglobulin clot lysishomocysteinefactor v leidenprothrombin g20210a Alleleprotein Cprotein Santithrombin Iii5,10 mthfr Genepai-1 polymorphism Geneactivated protein c resistance\n\ncaption (table-wrap): table 2\n\npatient datapatientagemiscarriagesnormal birthsdefectoutcome on lmw Heparin1272 in first trimester 1 in second trimester1mthfr c677t homozygous a1298c heterozygousn/a2412 in first trimester0mthfr c677t homozygousn/a3392 in first trimester1mthfr c677t homozygous Pai-1 heterozygous 4g/5gpregnancy with successful Delivery4442 in first trimester0mthfr c677t homozygouspregnancy with successful Delivery5271 in first trimester3mthfr c677t homozygous Pai-1 heterozygous 4g/5gn/a6346 in first trimester3mthfr c677t homozygous Pai-1 heterozygous 4g/5gpregnant, in third trimester7322 in first trimester2mthfr c677t homozygousn/a8403 in first trimester0mthfr c677t homozygous Pai-1 homozygous 4g/4gn/a\nwe reviewed the literature IN order to FIND EVIDENCE to SUPPORT OR REFUTE the ASSOCIATION between mthfr mutations and adverse Pregnancy outcomes, and to guide us in managing these patients.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 1127), ('INCOMPLETE_EVIDENCE', 1139), ('INCOMPLETE_EVIDENCE', 1144), ('INCOMPLETE_EVIDENCE', 1156), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1164), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1167), ('SUPERFICIAL_RELATIONSHIP', 1178)]	7	[('CHEBI_29940', 'hydridophosphorus(1+)', 100, 'Phosphatidyl'), ('GO_0071735', 'IgG immunoglobulin complex', 120, 'IgGβ2'), ('GO_0071754', 'IgM immunoglobulin complex, circulating', 155, 'IgM'), ('GO_0071736', 'IgG immunoglobulin complex, circulating', 163, 'IgGLupus'), ('CHEBI_83226', 'N(omega)-phospho-L-arginine(1-) residue', 172, 'anticoagulantPlasminogenEuglobulin'), ('GO_0006965', 'positive regulation of biosynthetic process of antibacterial peptides active against Gram-positive bacteria', 172, 'anticoagulantPlasminogenEuglobulin'), ('SO_0001023', 'allele', 264, 'alleleProtein'), ('PR_000004893', 'complement C1r subcomponent-like protein', 278, 'CProtein'), ('PR_000014428', 'SAC3 domain-containing protein 1', 287, 'SAntithrombin III5'), ('PR_000003770', 'all-trans-retinol dehydrogenase [NAD(+)] ADH4', 306, '10'), ('SO_0000704', 'gene', 315, 'genePAI'), ('PR_000000037', 'BMP receptor type-2', 322, '-1'), ('SO_0000401', 'gene_attribute', 338, 'geneActivated'), ('CHEBI_72475', 'acetoguanamine', 473, 'heparin1272'), ('PR_000014702', 'plasminogen activator inhibitor 1', 667, 'PAI-1'), ('GO_0033275', 'actin-myosin filament sliding', 717, 'delivery4442'), ('GO_0006952', 'defense response', 797, 'delivery5271'), ('PR_000014702', 'plasminogen activator inhibitor 1', 852, 'PAI-1'), ('PR_000014702', 'plasminogen activator inhibitor 1', 926, 'PAI-1'), ('PR_000014702', 'plasminogen activator inhibitor 1', 1074, 'PAI-1'), ('GO_0007565', 'female pregnancy', 1226, 'pregnancy')]
S180-PMC2430236	PMC2430236	6/2008	S180-PMC2430236	['oxidative pathways and alteration of maternal host–Defense mechanisms\npm CAN induce a broad polyclonal Expression of cytokines and chemokines in Respiratory Epithelium (sioutas et al.']	[('INCOMPLETE_EVIDENCE', 73)]	1	[('GO_0006952', 'defense response', 51, 'defense'), ('GO_0010467', 'gene expression', 103, 'expression'), ('UBERON_0004802', 'respiratory tract epithelium', 145, 'respiratory epithelium')]
S201-PMC2430236	PMC2430236	6/2008	S201-PMC2430236	['public health IMPLICATIONS\nPregnant women OFTEN want to know what they can do to increase the LIKELIHOOD of the Delivery Of a healthy Child [seecentre for health and environment research (2007)for examples of RECOMMENDATIONS given to Pregnant women].']	[('IMPORTANT_CONSIDERATION', 14), ('PROBABLE_UNDERSTANDING', 42), ('PROBABLE_UNDERSTANDING', 94), ('FUTURE_WORK', 209)]	4	[('GO_0007565', 'female pregnancy', 27, 'Pregnant'), ('GO_0006952', 'defense response', 112, 'delivery of ... child'), ('GO_0007565', 'female pregnancy', 234, 'pregnant')]
S177-PMC2644268	PMC2644268	3/2009	S177-PMC2644268	['microorganisms are stressors and NORMALLY initiate Defense mechanisms mediated by the ‘computer’.']	[('PROBABLE_UNDERSTANDING', 33)]	1	[('GO_0006952', 'defense response', 51, 'defense')]
S102-PMC3120196	PMC3120196	7/2011	S102-PMC3120196	['the Pancreatic Β-Cell is PARTICULARLY susceptible to oxidative stress because of a weak antioxidant Defense (3).']	[('ANOMALY_CURIOUS_FINDING', 25)]	1	[('CL_0000173', 'pancreatic D cell', 4, 'pancreatic β-cell'), ('UBERON_0001264', 'pancreas', 4, 'pancreatic'), ('GO_0006952', 'defense response', 100, 'defense')]
S199-PMC3138750	PMC3138750	7/2011	S199-PMC3138750	['furthermore, the diet-dependent Regulation Of Glucocorticoid Receptor Signaling between juvenile and adult stage and the resulting increased Glucocorticoid Receptor Signaling at stage 188 dpn in hp offspring SUGGESTS that hp offspring was in a kind of alarm alert (activated Defence) at Adult stage.']	[('INCOMPLETE_EVIDENCE', 208)]	1	[('GO_0032929', 'negative regulation of superoxide anion generation', 32, 'regulation of glucocorticoid receptor signaling'), ('CHEBI_24261', 'glucocorticoid', 46, 'glucocorticoid'), ('CHEBI_24261', 'glucocorticoid', 141, 'glucocorticoid'), ('GO_0009740', 'gibberellic acid mediated signaling pathway', 156, 'receptor signaling'), ('GO_0006952', 'defense response', 275, 'defence'), ('UBERON_0007023', 'adult organism', 287, 'adult')]
S52-PMC3171895	PMC3171895	9/2011	S52-PMC3171895	['it HAS BEEN SUGGESTED that adequate Selenium status is IMPORTANT for antioxidant Defence and MAY BE a POTENTIAL FACTOR in women at risk of Preeclampsia; this HYPOTHESIS HAS BEEN FURTHER JUSTIFIED by the reduced Expression and activities of Glutathione peroxidase FOUND in maternal, Fetal, and Placental samples taken from 25 Preeclamptic Pregnancies, when compared to 27 normal controls in our RECENT cross-sectional retrospective STUDY [32].']	[('INCOMPLETE_EVIDENCE', 3), ('IMPORTANT_CONSIDERATION', 55), ('INCOMPLETE_EVIDENCE', 93), ('INCOMPLETE_EVIDENCE', 102), ('SUPERFICIAL_RELATIONSHIP', 112), ('INCOMPLETE_EVIDENCE', 158), ('INCOMPLETE_EVIDENCE', 169), ('INCOMPLETE_EVIDENCE', 178), ('IMPORTANT_CONSIDERATION', 186), ('INCOMPLETE_EVIDENCE', 263), ('INCOMPLETE_EVIDENCE', 394)]	11	[('CHEBI_27568', 'selenium atom', 36, 'selenium'), ('GO_0006952', 'defense response', 81, 'defence'), ('GO_0007128', 'meiotic prophase I', 139, 'preeclampsia'), ('GO_0010467', 'gene expression', 211, 'expression'), ('CHEBI_16856', 'glutathione', 240, 'glutathione'), ('UBERON_0000922', 'embryo', 282, 'fetal'), ('UBERON_0001987', 'placenta', 293, 'placental'), ('GO_0007565', 'female pregnancy', 325, 'preeclamptic'), ('GO_0007565', 'female pregnancy', 338, 'pregnancies')]
S180-PMC3342123	PMC3342123	3/2012	S180-PMC3342123	['THEREFORE, Expression profiles at weaning and adult stages POINT to an alarm alert (activated Defence) in lp offspring.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 59)]	2	[('GO_0010467', 'gene expression', 11, 'expression'), ('GO_0006952', 'defense response', 94, 'defence')]
S150-PMC3403156	PMC3403156	7/2012	S150-PMC3403156	"[""Ros Generation normally is balanced by the cell's antioxidant Defense mechanisms, which maintains its redox state and is IMPORTANT in physiological Regulation in both the Embryo and fetus.""]"	[('IMPORTANT_CONSIDERATION', 121)]	1	[('CHEBI_8756', 'RNA (poly(A))', 0, 'ROS'), ('GO_0031099', 'regeneration', 0, 'ROS generation'), ('GO_0006952', 'defense response', 62, 'defense'), ('GO_0065007', 'biological regulation', 148, 'regulation'), ('UBERON_0000922', 'embryo', 171, 'embryo')]
S116-PMC3415261	PMC3415261	7/2012	S116-PMC3415261	['at the end of the second week of Life, Rat Gut lp increases the content of Cd8+Cd5+ and Cd8 Αβ + cells, which SEEMS to reflect an increasing colonization and Defense provided by Cd8+ Cell subsets originating from the Thymus [31].']	[('ANOMALY_CURIOUS_FINDING', 110)]	1	[('UBERON_0000104', 'life cycle', 33, 'life'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 39, 'rat'), ('UBERON_0001555', 'digestive tract', 43, 'gut'), ('PR_000005170', 'CD37 molecule', 75, 'CD8'), ('PR_000001204', 'C-C chemokine receptor type 8', 79, 'CD5'), ('PR_000001309', 'CD70 molecule', 88, 'CD8 αβ'), ('GO_0006952', 'defense response', 158, 'defense'), ('CL_0000918', 'Tc2 cell', 178, 'CD8+ cell'), ('UBERON_0002370', 'thymus', 217, 'thymus')]
S61-PMC3458940	PMC3458940	9/2012	S61-PMC3458940	['for this purpose, we selected Bmp7, Foxa1, Pax2, and Wnt7B, which HAVE BEEN IMPLICATED in Kidney Development, Water Transport, and Defense/protection mechanism against injury[15],[20],[21],[22],[23].']	[('INCOMPLETE_EVIDENCE', 66), ('SUPERFICIAL_RELATIONSHIP', 76)]	2	[('PR_000000168', 'BMP7', 30, 'Bmp7'), ('PR_000007606', 'forkhead box protein B2', 36, 'Foxa1'), ('PR_000012318', 'paired box protein Pax-6', 43, 'Pax2'), ('PR_000017453', 'protein Wnt-9b', 53, 'Wnt7b'), ('GO_0001822', 'kidney development', 90, 'kidney development'), ('UBERON_0002113', 'kidney', 90, 'kidney'), ('CHEBI_15377', 'water', 110, 'water'), ('GO_0006833', 'water transport', 110, 'water transport'), ('GO_0006952', 'defense response', 131, 'defense')]
S93-PMC3472225	PMC3472225	8/2012	S93-PMC3472225	['the integration of Piwi rnas into Animal germ line providing Defense against specific Transposable Elements SEEMS to fit the definition of lamarckian evolution equally well [70,71].']	[('ANOMALY_CURIOUS_FINDING', 108)]	1	[('PR_000013039', 'POU domain, class 3, transcription factor 2', 19, 'Piwi'), ('NCBITaxon_33208', 'Metazoa', 34, 'animal'), ('GO_0006952', 'defense response', 61, 'defense'), ('SO_0000101', 'transposable_element', 86, 'transposable elements')]
S156-PMC3472225	PMC3472225	8/2012	S156-PMC3472225	['the case of the prokaryotic crispr-cas system of Defense against mobile elements including Plasmids and Viruses is an INTERESTING and much stronger case as covered by the author in a previous publication [67].']	[('ANOMALY_CURIOUS_FINDING', 118)]	1	[('GO_0006952', 'defense response', 49, 'defense'), ('SO_0000155', 'plasmid', 91, 'plasmids'), ('NCBITaxon_1', 'root', 104, 'viruses')]
S157-PMC3472225	PMC3472225	8/2012	S157-PMC3472225	['NEVERTHELESS, a stochastic event and not the need for Viral Defense lead to integration and Antisense transcription of part of the Invader’s Genome.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0)]	1	[('NCBITaxon_1', 'root', 54, 'viral'), ('GO_0006952', 'defense response', 60, 'defense'), ('SO_0000077', 'antisense', 92, 'antisense'), ('NCBITaxon_1', 'root', 131, 'invader'), ('SO_0001026', 'genome', 141, 'genome')]
S48-PMC3488908	PMC3488908	4/2010	S48-PMC3488908	['ALTHOUGH these pathways are IMPORTANT in Defense from parasitic Infection, they are also CRUCIAL much earlier in development for fetal survival.']	[('ANOMALY_CURIOUS_FINDING', 0), ('IMPORTANT_CONSIDERATION', 28), ('IMPORTANT_CONSIDERATION', 89)]	3	[('GO_0006952', 'defense response', 41, 'defense'), ('GO_0007586', 'digestion', 64, 'infection')]
S58-PMC3488908	PMC3488908	4/2010	S58-PMC3488908	['Antigen encounter in peripheral Tissues induces migration and maturation in regional Nodes.29the Development Of these Responses is naturally DIFFICULT to study in Humans.']	[('DIFFICULT_TASK', 141)]	1	[('CHEBI_59132', 'antigen', 0, 'Antigen'), ('UBERON_0000479', 'tissue', 32, 'tissues'), ('UBERON_0000023', 'wing', 85, 'nodes'), ('GO_0006952', 'defense response', 97, 'development of ... responses'), ('NCBITaxon_9606', 'Homo sapiens', 163, 'humans')]
S558-PMC3532199	PMC3532199	11/2012	S558-PMC3532199	['date/Gestation edits: to check INCONSISTENCIES between the Delivery Gestation calculated and other date inconsistencies (e.g., between Birth date/time and Delivery date/time).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 31)]	1	[('GO_0006266', 'DNA ligation', 5, 'Gestation'), ('GO_0006952', 'defense response', 59, 'delivery gestation'), ('GO_0007567', 'parturition', 135, 'birth'), ('GO_0007567', 'parturition', 155, 'delivery')]
S111-PMC3586494	PMC3586494	2/2013	S111-PMC3586494	['Pancreatic Β Cells are PARTICULARLY sensitive to Reactive Oxygen Species because they are low in enzymatic antioxidant Defense equipment [49].']	[('ANOMALY_CURIOUS_FINDING', 23)]	1	[('CL_0002072', 'nodal myocyte', 0, 'Pancreatic β cells'), ('UBERON_0001264', 'pancreas', 0, 'Pancreatic'), ('CHEBI_26523', 'reactive oxygen species', 49, 'reactive oxygen species'), ('GO_0006952', 'defense response', 119, 'defense')]
S48-PMC3702245	PMC3702245	6/2013	S48-PMC3702245	['Vitamin D HAS BEEN SHOWN to upregulate Endogenous Synthesis Of Cathelicidin, a potent Antimicrobial peptide, in response to Microbial Invasion, via activation of toll-like receptors on microphages and Monocytes.6,24given that Antimicrobial peptides provide rapid Defense against invading pathogens, it is PLAUSIBLE that Vitamin D plays a ROLE in host defense against infections in both mother and offspring.']	[('INCOMPLETE_EVIDENCE', 10), ('INCOMPLETE_EVIDENCE', 305), ('SUPERFICIAL_RELATIONSHIP', 338)]	3	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0009790', 'embryo development', 39, 'endogenous'), ('GO_0007608', 'sensory perception of smell', 50, 'synthesis of ...'), ('CHEBI_3364', 'Canthiumine', 63, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 63, 'cathelicidin'), ('CHEBI_65381', 'albizoside C', 86, 'antimicrobial'), ('NCBITaxon_10088', 'Mus <genus>', 124, 'microbial'), ('GO_0007586', 'digestion', 134, 'invasion'), ('CL_0000576', 'monocyte', 201, 'monocytes'), ('CHEBI_65381', 'albizoside C', 226, 'antimicrobial'), ('GO_0006952', 'defense response', 263, 'defense'), ('CHEBI_27300', 'vitamin D', 320, 'vitamin D')]
S46-PMC3829803	PMC3829803	11/2013	S46-PMC3829803	['these cytokines trigger a rapid and strong Innate Defense against many Viruses, leading to the transcription of several hundred isgs Controlled by the ifn-stimulated Gene factor 3 (Isgf3) Complex [29].']	[('DIFFICULT_TASK', 188)]	1	[('GO_0007631', 'feeding behavior', 43, 'innate'), ('GO_0006952', 'defense response', 50, 'defense'), ('GO_0007601', 'visual perception', 71, 'viruses'), ('NCBITaxon_1', 'root', 71, 'viruses'), ('GO_0065007', 'biological regulation', 133, 'controlled'), ('SO_0000704', 'gene', 166, 'gene'), ('PR_000009158', 'inositol 1,4,5-trisphosphate receptor type 1', 181, 'ISGF3'), ('GO_0032991', 'protein-containing complex', 188, 'complex')]
S98-PMC3877972	PMC3877972	12/2013	S98-PMC3877972	['caption (table-wrap): table 2\n\nintrapartum COMPLICATIONS among full-term lbw neonates according to mode of Deliverymode of Deliverycesarean sectionnormal Vaginal Deliverypn%n% normal102892.061990.0\xa0mild asphyxia726.4273.90.039severe asphyxia111.040.60.385stillbirth60.5385.5<0.001\n\ncaption (table-wrap): table 3\n\noutcomes of full-term lbw neonates according to mode of Deliverymode of Deliverycesarean sectionnormal Vaginal Deliveryp \xa0 n%n% \xa0healthy110597.264891.5\xa0complications161.460.80.349deformities50.460.80.229deaths111.0486.8<0.001\nanalysis of prognosis of full-term lbw infants and infants with normal Birth weight SHOWED the occurrence of stillbirth, severe neonatal asphyxia, and neonatal death to be 2.42%, 0.83%, and 3.49%, respectively, among full-term lbw infants and 0.14%, 0.11%, and 0.14%, respectively, among full-term infants with normal Birth weight.']	[('PROBLEM_COMPLICATION', 43), ('INCOMPLETE_EVIDENCE', 623)]	2	[('GO_0008219', 'cell death', 107, 'deliveryMode'), ('GO_0031047', 'gene silencing by RNA', 123, 'deliveryCesarean'), ('GO_0007601', 'visual perception', 154, 'vaginal'), ('UBERON_0001987', 'placenta', 154, 'vaginal'), ('GO_0006952', 'defense response', 162, 'deliveryPn'), ('GO_0008219', 'cell death', 369, 'deliveryMode'), ('GO_0031047', 'gene silencing by RNA', 385, 'deliveryCesarean'), ('UBERON_0001987', 'placenta', 416, 'vaginal'), ('GO_0007567', 'parturition', 424, 'deliveryP'), ('GO_0007567', 'parturition', 610, 'birth'), ('GO_0007567', 'parturition', 857, 'birth')]
S128-PMC3973641	PMC3973641	4/2014	S128-PMC3973641	['with this fact in mind, in OUR STUDY, the high hcy concentration in maternal-fetal circulation COULD lead to oxidative stress and, as a CONSEQUENCE, a decreased efficacy of Defense mechanisms such as Gsh availability.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 27), ('INCOMPLETE_EVIDENCE', 95), ('PROBABLE_UNDERSTANDING', 136)]	3	[('GO_0006952', 'defense response', 173, 'defense'), ('CHEBI_16856', 'glutathione', 200, 'GSH')]
S228-PMC4152245	PMC4152245	9/2014	S228-PMC4152245	['the activity of sod IS KNOWN to serve protective function for the elimination of Reactive Free Radicals and THUS it represents an IMPORTANT antioxidant Defense in NEARLY ALL cells exposed to oxygen[67],[68].']	[('INCOMPLETE_EVIDENCE', 20), ('PROBABLE_UNDERSTANDING', 108), ('IMPORTANT_CONSIDERATION', 130), ('PROBABLE_UNDERSTANDING', 163)]	4	[('CHEBI_26523', 'reactive oxygen species', 81, 'reactive free radicals'), ('GO_0006952', 'defense response', 152, 'defense')]
S135-PMC4160835	PMC4160835	9/2014	S135-PMC4160835	['in a MODEL of the Human Intestinal microbial ecosystem, as well as in Rat studies, it HAS BEEN SHOWN that chronic exposure of cpf selectively altered the Intestinal microflora.55proliferation of the total Intestinal flora was observed, MAINLY due to an increase in certain subpopulations such as the enterococcus spp and bacteroides spp, while there was a decrease in the numbers of beneficial bacteria such as bifidobacteria and lactobacilli.55\n\nhigher Intake of Secondary Plant Metabolites\na majority of studies comparing the contents of secondary Plant Metabolites in organically vs conventionally Grown fruits and vegetables report higher contents of these Compounds in Organic products.285657brandt et al 28reported substantially higher contents of defence-related Secondary Metabolites, represented by Phenolic Acids; other Defence Compounds (tannins, Alkaloids, Chalcones, Stilbenes, Flavanones and Flavanols, Hop Acids, coumarins and aurones), and total phenolics.']	[('INCOMPLETE_EVIDENCE', 5), ('INCOMPLETE_EVIDENCE', 86), ('PROBABLE_UNDERSTANDING', 236)]	3	[('NCBITaxon_9606', 'Homo sapiens', 18, 'human'), ('UBERON_0000160', 'intestine', 24, 'intestinal'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 70, 'rat'), ('UBERON_0000160', 'intestine', 154, 'intestinal'), ('UBERON_0000160', 'intestine', 205, 'intestinal'), ('GO_0007631', 'feeding behavior', 454, 'intake'), ('CHEBI_26629', 'selenoamino acid', 464, 'secondary'), ('NCBITaxon_33208', 'Metazoa', 474, 'plant'), ('CHEBI_25212', 'metabolite', 480, 'metabolites'), ('NCBITaxon_33208', 'Metazoa', 550, 'plant'), ('CHEBI_25212', 'metabolite', 556, 'metabolites'), ('GO_0040007', 'growth', 601, 'grown'), ('CHEBI_36357', 'polyatomic entity', 661, 'compounds'), ('CHEBI_77514', '6-phenylundecane', 674, 'organic'), ('CHEBI_26645', 'semiochemical', 770, 'secondary metabolites'), ('CHEBI_25981', 'phenylacetyl-CoAs', 808, 'phenolic acids'), ('GO_0006952', 'defense response', 830, 'defence'), ('CHEBI_36357', 'polyatomic entity', 838, 'compounds'), ('CHEBI_22315', 'alkaloid', 858, 'alkaloids'), ('CHEBI_23089', 'chelate-forming peptide', 869, 'chalcones'), ('CHEBI_26675', 'silicic acid', 880, 'stilbenes'), ('CHEBI_28861', 'gibberellin A8', 891, 'flavanones'), ('CHEBI_28798', 'rubber particle', 906, 'flavanols'), ('CHEBI_24857', 'iodic acid', 917, 'hop acids')]
S136-PMC4160835	PMC4160835	9/2014	S136-PMC4160835	['the authors ESTIMATE, based ON a meta-analysis of 65 papers, that IF a Person changes from Consuming exclusively conventional fruit and vegetables to Consuming the organic alternatives of the same products in the same amounts, the intake of all Secondary Metabolites would increase by APPROXIMATELY 12%, and the intake of more specifically Defence-RELATED Secondary Metabolites would increase by APPROXIMATELY 16%.28WHETHER such a difference has health-related IMPLICATIONS remains to be shown.']	[('INCOMPLETE_EVIDENCE', 12), ('ANOMALY_CURIOUS_FINDING', 28), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 66), ('INCOMPLETE_EVIDENCE', 285), ('SUPERFICIAL_RELATIONSHIP', 348), ('INCOMPLETE_EVIDENCE', 396), ('ANOMALY_CURIOUS_FINDING', 414), ('ANOMALY_CURIOUS_FINDING', 414), ('IMPORTANT_CONSIDERATION', 461)]	9	[('NCBITaxon_10088', 'Mus <genus>', 71, 'person'), ('GO_0007631', 'feeding behavior', 91, 'consuming'), ('GO_0007631', 'feeding behavior', 150, 'consuming'), ('CHEBI_26645', 'semiochemical', 245, 'secondary metabolites'), ('GO_0006952', 'defense response', 340, 'defence'), ('CHEBI_26629', 'selenoamino acid', 356, 'secondary'), ('CHEBI_25212', 'metabolite', 366, 'metabolites')]
S28-PMC4161944	PMC4161944	9/2014	S28-PMC4161944	['this altered immunological priming is not maladaptive, RATHER, the fetus and neonate are challenged with balancing Defense against Infection, minimizing POTENTIALLY harmful inflammation, and mitigating colonization by microbes as it develops and transitions from the relatively protected Womb to the external world (9).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 55), ('INCOMPLETE_EVIDENCE', 153)]	2	[('GO_0006952', 'defense response', 115, 'defense'), ('GO_0007586', 'digestion', 131, 'infection'), ('UBERON_0002396', 'vomer', 288, 'womb')]
S233-PMC4169551	PMC4169551	9/2014	S233-PMC4169551	['the nutritional environment of the Gestating female MUST BE considered with CAUTION considering the Defence capacity of the offspring.']	[('IMPORTANT_CONSIDERATION', 52), ('INCOMPLETE_EVIDENCE', 76)]	2	[('GO_0007565', 'female pregnancy', 35, 'gestating'), ('GO_0006952', 'defense response', 100, 'defence')]
S37-PMC4171568	PMC4171568	9/2014	S37-PMC4171568	['oxidative stress and the benefits of supplementation\noxidative stress occurs when the antioxidant Defence capacity of an Organism is UNABLE TO balance the Production Of Reactive Oxygen Species (Ros) and Reactive Nitrogen Species (rns), as generated from normal Oxidative Metabolism [19].']	[('DIFFICULT_TASK', 133)]	1	[('GO_0006952', 'defense response', 98, 'defence'), ('NCBITaxon_1', 'root', 121, 'organism'), ('GO_1903409', 'reactive oxygen species biosynthetic process', 155, 'production of reactive oxygen species'), ('CHEBI_26523', 'reactive oxygen species', 169, 'reactive oxygen species'), ('GO_0016246', 'RNA interference', 194, 'ROS'), ('CHEBI_62764', 'reactive nitrogen species', 203, 'reactive nitrogen species'), ('GO_0045333', 'cellular respiration', 261, 'oxidative metabolism')]
S13-PMC4172064	PMC4172064	9/2014	S13-PMC4172064	['given equal exposure, this ALONE would render boys more SUSCEPTIBLE than girls to the Airway-narrowing EFFECTS of the inflammation and ASSOCIATED edema that accompanies activation of host anti-Viral Defense in the Respiratory Tract.']	[('ANOMALY_CURIOUS_FINDING', 27), ('SUPERFICIAL_RELATIONSHIP', 56), ('SUPERFICIAL_RELATIONSHIP', 103), ('SUPERFICIAL_RELATIONSHIP', 135)]	4	[('UBERON_0001005', 'respiratory airway', 86, 'airway'), ('NCBITaxon_1', 'root', 193, 'viral'), ('GO_0006952', 'defense response', 199, 'defense'), ('UBERON_0000065', 'respiratory tract', 214, 'respiratory tract')]
S86-PMC4193194	PMC4193194	10/2014	S86-PMC4193194	['the existence of ros during normal Gestation is a fact (yang et al.,2012), INDICATING that an impairment of the natural antioxidant Defense mechanism is PROBABLY implied in pe (karacay et al.,2010).']	[('INCOMPLETE_EVIDENCE', 75), ('PROBABLE_UNDERSTANDING', 153)]	2	[('GO_0007565', 'female pregnancy', 35, 'gestation'), ('GO_0006952', 'defense response', 132, 'defense')]
S34-PMC4258799	PMC4258799	11/2014	S34-PMC4258799	['in vitro , the risk of oxidative stress development is greater than in vivo [13] and its negative IMPACT MAY BE amplified DUE TO the lack of physiological Defense mechanisms, absence of natural antioxidants and the presence of multiple POTENTIAL sources of Ros [4].']	[('SUPERFICIAL_RELATIONSHIP', 98), ('INCOMPLETE_EVIDENCE', 105), ('PROBLEM_COMPLICATION', 122), ('INCOMPLETE_EVIDENCE', 236)]	4	[('GO_0006952', 'defense response', 155, 'defense'), ('CHEBI_8756', 'RNA (poly(A))', 257, 'ROS')]
S176-PMC4303849	PMC4303849	1/2015	S176-PMC4303849	['conjointly, these endogenous Antibiotics provide an efficient mechanism of front-line Defense SINCE they have the capacity to kill a wide variety of microorganisms throughout the female Reproductive Tract [160].']	[('PROBABLE_UNDERSTANDING', 94)]	1	[('CHEBI_33282', 'antibacterial agent', 29, 'antibiotics'), ('GO_0006952', 'defense response', 86, 'defense'), ('GO_0000003', 'reproduction', 186, 'reproductive'), ('UBERON_0001018', 'axon tract', 199, 'tract')]
S142-PMC4346113	PMC4346113	3/2015	S142-PMC4346113	['inflammation HAS BEEN described as an adaptation to the disruption of Homeostasis at a cellular and Tissue level and AFFECTS many IMPORTANT processes, such as host Defense, Tissue remodeling and Repair, and the Regulation Of Metabolism.']	[('INCOMPLETE_EVIDENCE', 13), ('SUPERFICIAL_RELATIONSHIP', 117), ('IMPORTANT_CONSIDERATION', 130)]	3	[('GO_0042592', 'homeostatic process', 70, 'homeostasis'), ('UBERON_0000479', 'tissue', 100, 'tissue'), ('GO_0006952', 'defense response', 164, 'defense'), ('UBERON_0000479', 'tissue', 173, 'tissue'), ('GO_0006281', 'DNA repair', 195, 'repair'), ('GO_0009894', 'regulation of catabolic process', 211, 'regulation of metabolism')]
S14-PMC4354412	PMC4354412	3/2015	S14-PMC4354412	['Milk harbors bacteria, antibacterial substances such as lysozyme and Lactoferrin, Antibodies, cytokines, growth factors, and hormones which are KNOWN to be important for the immune Defense and the Development Of the Intestinal Epithelial Cells (Iecs) of the offspring [reviewed in ref.']	[('INCOMPLETE_EVIDENCE', 144)]	1	[('UBERON_0001913', 'milk', 0, 'Milk'), ('PR_000002198', 'catenin beta-1', 69, 'lactoferrin'), ('GO_0042571', 'immunoglobulin complex, circulating', 82, 'antibodies'), ('GO_0006952', 'defense response', 181, 'defense'), ('GO_0009589', 'detection of UV', 197, 'development of ... epithelial cells'), ('CL_0002516', 'interrenal chromaffin cell', 216, 'intestinal epithelial cells ... IECs'), ('UBERON_0000160', 'intestine', 216, 'intestinal'), ('UBERON_0000483', 'epithelium', 227, 'epithelial')]
S43-PMC4386645	PMC4386645	3/2015	S43-PMC4386645	['particularly the sophisticated Intestinal Epithelium is strongly dependent on a proper development in order to fulfill its widespread functions ranging from Defense of Antigens to absorption of IMPORTANT Nutrients.']	[('IMPORTANT_CONSIDERATION', 194)]	1	[('UBERON_0001277', 'intestinal epithelium', 31, 'intestinal epithelium'), ('GO_0006952', 'defense response', 157, 'defense'), ('CHEBI_59132', 'antigen', 168, 'antigens'), ('CHEBI_33284', 'nutrient', 204, 'nutrients')]
S183-PMC4448820	PMC4448820	5/2015	S183-PMC4448820	['● vdd in Humans has a modest EFFECT on Innate Immunity, with the EXCEPTION of Macrophage function and Production Of cathelicidins and Defensins (112).']	[('SUPERFICIAL_RELATIONSHIP', 29), ('ANOMALY_CURIOUS_FINDING', 65)]	2	[('NCBITaxon_9606', 'Homo sapiens', 9, 'humans'), ('GO_0045087', 'innate immune response', 39, 'innate immunity'), ('CL_0000235', 'macrophage', 78, 'macrophage'), ('GO_0008283', 'cell proliferation', 102, 'production of ...'), ('GO_0006952', 'defense response', 134, 'defensins')]
S625-PMC4448820	PMC4448820	5/2015	S625-PMC4448820	['as discussed by Wg 1, zinc IS KNOWN to play a CRITICAL ROLE in the integrity, function, and maintenance of host Defense systems (384, 352, 353) (summarized in text box 22 ).']	[('INCOMPLETE_EVIDENCE', 27), ('IMPORTANT_CONSIDERATION', 46), ('SUPERFICIAL_RELATIONSHIP', 55)]	3	[('PR_000017413', 'WAP, Kazal, immunoglobulin, Kunitz and NTR domain-containing protein 2', 16, 'WG 1'), ('GO_0006952', 'defense response', 112, 'defense')]
S58-PMC4530571	PMC4530571	4/2015	S58-PMC4530571	['Nutrition and developmental programming\ncertain Nutrients, such as antioxidants and saturated Fatty Acids MAY REPRESENT a LINK between obesity and asthma [14], AS they play an important ROLE in oxidative Lung damage and decreased Lung Defense against environmental hazards [41].']	[('INCOMPLETE_EVIDENCE', 106), ('PROBABLE_UNDERSTANDING', 110), ('SUPERFICIAL_RELATIONSHIP', 122), ('PROBABLE_UNDERSTANDING', 160), ('SUPERFICIAL_RELATIONSHIP', 186)]	5	[('GO_0006754', 'ATP biosynthetic process', 0, 'Nutrition'), ('CHEBI_33284', 'nutrient', 48, 'nutrients'), ('CHEBI_35366', 'fatty acid', 94, 'fatty acids'), ('UBERON_0002048', 'lung', 204, 'lung'), ('GO_0006412', 'translation', 230, 'lung'), ('UBERON_0002048', 'lung', 230, 'lung'), ('GO_0006952', 'defense response', 235, 'defense')]
S21-PMC4574972	PMC4574972	9/2015	S21-PMC4574972	['[2–6] the Neonatal Period is CRITICAL in terms of Mucosal Defence and Immunologic priming and presence of aberrant Gut bacteria during this time COULD THEREFORE have profound EFFECTS on Immune Maturation.']	[('IMPORTANT_CONSIDERATION', 29), ('INCOMPLETE_EVIDENCE', 145), ('PROBABLE_UNDERSTANDING', 151), ('SUPERFICIAL_RELATIONSHIP', 175)]	4	[('UBERON_0007221', 'neonate stage', 10, 'neonatal period'), ('UBERON_0000344', 'mucosa', 50, 'mucosal'), ('GO_0006952', 'defense response', 58, 'defence'), ('UBERON_0000913', 'interstitial fluid', 70, 'immunologic'), ('UBERON_0001555', 'digestive tract', 115, 'gut'), ('GO_0050900', 'leukocyte migration', 186, 'immune maturation'), ('UBERON_0002405', 'immune system', 186, 'immune')]
S166-PMC4670104	PMC4670104	12/2015	S166-PMC4670104	['collectively, our results SUGGEST that Hepatic-driven proteins that positively COVARY with inflammation are INVOLVED in host Defense.']	[('INCOMPLETE_EVIDENCE', 26), ('SUPERFICIAL_RELATIONSHIP', 79), ('SUPERFICIAL_RELATIONSHIP', 108)]	3	[('UBERON_0002107', 'liver', 39, 'hepatic'), ('GO_0006952', 'defense response', 125, 'defense')]
S188-PMC4670104	PMC4670104	12/2015	S188-PMC4670104	['our results SUGGEST that proteins that maintain integrity of the Ecm are down-regulated, POSSIBLY reflecting Metabolic rebalancing between host Defense and healing mechanisms [82].']	[('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 89)]	2	[('GO_0031012', 'extracellular matrix', 65, 'ECM'), ('GO_0008152', 'metabolic process', 109, 'metabolic'), ('GO_0006952', 'defense response', 144, 'defense')]
S19-PMC4703052	PMC4703052	1/2016	S19-PMC4703052	['our FOCUS is on Humans, and we consider the relative costs and effectiveness of each subsystem of Defense, and PROPOSE that the balance of investment in innate versus Acquired Immunity will be shaped by three ecological FACTORS during sensitive periods of Immune Development: (i) the availability of nutritional resources, (ii) the intensity of pathogen exposure and (iii) signals of extrinsic mortality risk.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('INCOMPLETE_EVIDENCE', 111), ('SUPERFICIAL_RELATIONSHIP', 220)]	3	[('NCBITaxon_9606', 'Homo sapiens', 16, 'humans'), ('GO_0006952', 'defense response', 98, 'defense'), ('GO_0019624', 'atrazine catabolic process to isopropylamine', 167, 'acquired immunity'), ('GO_0001822', 'kidney development', 256, 'immune development'), ('UBERON_0002405', 'immune system', 256, 'immune')]
S89-PMC4703052	PMC4703052	1/2016	S89-PMC4703052	['it is DIFFICULT to isolate costs ASSOCIATED with the activation of innate versus acquired Defenses, SINCE in Humans the typical response involves both arms of immunity.']	[('DIFFICULT_TASK', 6), ('SUPERFICIAL_RELATIONSHIP', 33), ('PROBLEM_COMPLICATION', 100)]	3	[('GO_0006952', 'defense response', 90, 'defenses'), ('NCBITaxon_9606', 'Homo sapiens', 109, 'humans')]
S112-PMC4703052	PMC4703052	1/2016	S112-PMC4703052	['innate Defenses are mobilized quickly and provide a CRITICAL line of Defense against NOVEL pathogens, and responses do not change with subsequent exposures.']	[('IMPORTANT_CONSIDERATION', 52), ('FULL_UNKNOWN', 85)]	2	[('GO_0006952', 'defense response', 7, 'defenses'), ('GO_0006952', 'defense response', 69, 'defense')]
S148-PMC4703052	PMC4703052	1/2016	S148-PMC4703052	['hypotheses: investments in innate and acquired immunity in humans\nBASED on the relative costs and benefits of innate and acquired Immune defenses, we PROPOSE that local ecological conditions early in development INFLUENCE PATTERNS of investment across these subsystems of Defense.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 66), ('INCOMPLETE_EVIDENCE', 150), ('SUPERFICIAL_RELATIONSHIP', 212), ('SUPERFICIAL_RELATIONSHIP', 222)]	4	[('GO_0007566', 'embryo implantation', 130, 'immune'), ('UBERON_0002405', 'immune system', 130, 'immune'), ('GO_0006952', 'defense response', 272, 'defense')]
S159-PMC4703052	PMC4703052	1/2016	S159-PMC4703052	['in the absence of adequate nutrition, the Development and function Of the Immune System MAY BE constrained, with subsystems of Defense that require more resources DISPROPORTIONATELY AFFECTED.']	[('INCOMPLETE_EVIDENCE', 88), ('ANOMALY_CURIOUS_FINDING', 163), ('SUPERFICIAL_RELATIONSHIP', 182)]	3	[('GO_0002240', 'response to molecule of oomycetes origin', 42, 'development ... of ... immune system'), ('UBERON_0002405', 'immune system', 74, 'immune system'), ('GO_0006952', 'defense response', 127, 'defense')]
S234-PMC4703052	PMC4703052	1/2016	S234-PMC4703052	['conclusions\nimmune Defenses provide CRITICAL protection against infectious disease, but they REQUIRE resources to fuel their development and function.']	[('IMPORTANT_CONSIDERATION', 36), ('IMPORTANT_CONSIDERATION', 93)]	2	[('GO_0006952', 'defense response', 19, 'defenses')]
S235-PMC4703052	PMC4703052	1/2016	S235-PMC4703052	['we PROPOSE that the balance of investment in Innate versus Acquired Immunity is variable and that this balance is optimized in response to signals in the local environment due to the distinct profiles of costs and benefits ASSOCIATED with each type of Defense.']	[('INCOMPLETE_EVIDENCE', 3), ('SUPERFICIAL_RELATIONSHIP', 223)]	2	[('GO_0007631', 'feeding behavior', 45, 'innate'), ('GO_0019624', 'atrazine catabolic process to isopropylamine', 59, 'acquired immunity'), ('GO_0006952', 'defense response', 252, 'defense')]
S267-PMC4703052	PMC4703052	1/2016	S267-PMC4703052	['within-population analyses, preferably with prospectively collected data beginning in infancy, will be necessary to document Immune trade-offs in Individuals, and to CONSIDER the Life history and clinical IMPLICATIONS of DIFFERENT patterns of investment in innate versus acquired Defenses.']	[('FUTURE_WORK', 166), ('IMPORTANT_CONSIDERATION', 205), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 221)]	3	[('UBERON_0002405', 'immune system', 125, 'immune'), ('NCBITaxon_1', 'root', 146, 'individuals'), ('UBERON_0000104', 'life cycle', 179, 'life'), ('GO_0006952', 'defense response', 280, 'defenses')]
S394-PMC4703068	PMC4703068	8/2015	S394-PMC4703068	['a change in the microbiota promotes weight gain in dio by INTERACTING with a lymphotoxin-dependent Mucosal Defense pathway (upadhyay et\xa0al.']	[('SUPERFICIAL_RELATIONSHIP', 58)]	1	[('UBERON_0000344', 'mucosa', 99, 'mucosal'), ('GO_0006952', 'defense response', 107, 'defense')]
S88-PMC4857870	PMC4857870	5/2016	S88-PMC4857870	['these Phytochemicals play CRUCIAL ROLES in support of the antioxidant Defense system, and in their ability to reduce the low-grade inflammation.']	[('IMPORTANT_CONSIDERATION', 26), ('SUPERFICIAL_RELATIONSHIP', 34)]	2	[('CHEBI_26254', 'prenylnaphthoquinone', 6, 'phytochemicals'), ('GO_0006952', 'defense response', 70, 'defense')]
S267-PMC4871475	PMC4871475	5/2016	S267-PMC4871475	['Defecating and Urinating) in the Oft and Not loaded positively, and the time exploring the NOVEL object LOADED negatively in the ‘eliminating & avoiding novel object’ FACTOR.']	[('FULL_UNKNOWN', 91), ('SUPERFICIAL_RELATIONSHIP', 104), ('SUPERFICIAL_RELATIONSHIP', 167)]	3	[('GO_0006952', 'defense response', 0, 'defecating'), ('GO_0060073', 'micturition', 15, 'urinating'), ('UBERON_0004145', 'outflow tract', 33, 'OFT'), ('UBERON_0002551', 'interstitial nucleus of Cajal', 41, 'NOT')]
S313-PMC4871475	PMC4871475	5/2016	S313-PMC4871475	['PRIOR STUDIES have CONFIRMED that standing alert, high-pitched vocalisations, and Defecations in novelty tests are RELATED to negative emotional states in Pigs [32,45].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 19), ('SUPERFICIAL_RELATIONSHIP', 115)]	3	[('GO_0006952', 'defense response', 82, 'defecations'), ('NCBITaxon_10088', 'Mus <genus>', 155, 'pigs')]
S488-PMC4896250	PMC4896250	4/2016	S488-PMC4896250	['most patients with ad show reduced Expression of Antimicrobial peptides (amps), which MAY plays an IMPORTANT ROLE in host Defense against bacteria, Fungi, and Viruses infection.']	[('INCOMPLETE_EVIDENCE', 86), ('IMPORTANT_CONSIDERATION', 99), ('SUPERFICIAL_RELATIONSHIP', 109)]	3	[('GO_0010467', 'gene expression', 35, 'expression'), ('CHEBI_65381', 'albizoside C', 49, 'antimicrobial'), ('GO_0006952', 'defense response', 122, 'defense'), ('NCBITaxon_10088', 'Mus <genus>', 148, 'fungi'), ('NCBITaxon_1', 'root', 159, 'viruses')]
S3131-PMC4896250	PMC4896250	4/2016	S3131-PMC4896250	['it can be ASSUMED that the mobilization of the body Defense at a child in the acute period of the disease in the form of additional ejection Neurotransmitter and it CAN LEAD to a more rapid relief of obstruction Airway.']	[('PROBABLE_UNDERSTANDING', 10), ('INCOMPLETE_EVIDENCE', 165), ('SUPERFICIAL_RELATIONSHIP', 169)]	3	[('GO_0006952', 'defense response', 52, 'defense'), ('CHEBI_25512', 'neurotransmitter', 141, 'neurotransmitter'), ('UBERON_0001005', 'respiratory airway', 212, 'airway')]
S5551-PMC4896250	PMC4896250	4/2016	S5551-PMC4896250	['AS a Defence mechanism of body against oxydative stress, outsourcing of Vitamins is THEREFORE ESSENTIAL.']	[('PROBABLE_UNDERSTANDING', 0), ('PROBABLE_UNDERSTANDING', 84), ('IMPORTANT_CONSIDERATION', 94)]	3	[('GO_0006952', 'defense response', 5, 'defence'), ('CHEBI_33277', 'gamma-tocotrienol', 72, 'vitamins')]
S8338-PMC4896250	PMC4896250	4/2016	S8338-PMC4896250	['conclusions\nfull slit course was successfully implemented to all patients using modern tableted Allergen extract (produced in kazakhstan), DESPITE violations in Virus Defense system and Mucosal immunity system.']	[('ANOMALY_CURIOUS_FINDING', 139)]	1	[('CHEBI_50904', 'allergen', 96, 'allergen'), ('NCBITaxon_1', 'root', 161, 'virus'), ('GO_0006952', 'defense response', 167, 'defense'), ('UBERON_0000344', 'mucosa', 186, 'mucosal')]
S281-PMC4903143	PMC4903143	5/2016	S281-PMC4903143	['the field of nanotoxicology [294] is gathering more and more ATTENTION with the FINDING that these exceptionally small agents CAN bypass Human Defense mechanisms and penetrate into cells and disrupt biological function [295–297].']	[('INCOMPLETE_EVIDENCE', 61), ('INCOMPLETE_EVIDENCE', 80), ('INCOMPLETE_EVIDENCE', 126)]	3	[('NCBITaxon_9606', 'Homo sapiens', 137, 'human'), ('GO_0006952', 'defense response', 143, 'defense')]
S121-PMC4908484	PMC4908484	6/2016	S121-PMC4908484	['Ferritin, the main iron storage protein in Mammalian cells, IS CONSIDERED TO be the first line of Defense against iron Overload.']	[('INCOMPLETE_EVIDENCE', 60)]	1	[('PR_000007443', 'Fc receptor-like protein 4', 0, 'Ferritin'), ('NCBITaxon_40674', 'Mammalia', 43, 'mammalian'), ('GO_0006952', 'defense response', 98, 'defense'), ('GO_0007608', 'sensory perception of smell', 119, 'overload')]
S42-PMC4910734	PMC4910734	6/2015	S42-PMC4910734	['enzymes that reduce the Aldehyde Moiety to an Alcohol (Oh) Group are members of the Alcohol dehydrogenase (adh), the aldo-keto reductase, or the short-chain dehydrogenase/reductase superfamilies.3enzymes that oxidize the Aldehyde Moiety to an Acid Group include Aldehyde dehydrogenase (aldh) superfamily members as well as a few OTHER miscellaneous enzymes, such as Aldehyde oxidase, xanthine oxidase, and molybdenum hydroxylases.3of note, SOME endogenous Aldehydes are first conjugated with Glutathione, before being Detoxified by specific enzymes in the cellular antioxidant Defense system.3humans have evolved a variety of mechanisms to neutralize and prevent damage caused by endogenous Aldehydes, but an overload of exogenous Aldehydes, oxidative stress, and/or faulty Genes CAN sabotage the protective mechanisms.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 329), ('INCOMPLETE_EVIDENCE', 440), ('INCOMPLETE_EVIDENCE', 780)]	3	"[('CHEBI_48575', ""6-fluoro-2',5'-dioxo-2,3-dihydrospiro[chromene-4,4'-imidazolidine]-2-carboxamide"", 24, 'aldehyde moiety'), ('CHEBI_48274', 'tryptamine alkaloid', 46, 'alcohol (OH) group'), ('CHEBI_30879', 'alcohol', 84, 'alcohol'), ('CHEBI_48575', ""6-fluoro-2',5'-dioxo-2,3-dihydrospiro[chromene-4,4'-imidazolidine]-2-carboxamide"", 221, 'aldehyde moiety'), ('CHEBI_48373', 'amidyl group', 243, 'acid group'), ('CHEBI_17478', 'aldehyde', 262, 'aldehyde'), ('CHEBI_17478', 'aldehyde', 366, 'aldehyde'), ('CHEBI_17478', 'aldehyde', 456, 'aldehydes'), ('CHEBI_16856', 'glutathione', 492, 'glutathione'), ('GO_0070983', 'dendrite guidance', 518, 'detoxified'), ('GO_0006952', 'defense response', 577, 'defense'), ('CHEBI_17478', 'aldehyde', 691, 'aldehydes'), ('CHEBI_17478', 'aldehyde', 731, 'aldehydes'), ('SO_0000704', 'gene', 774, 'genes')]"
S174-PMC4910734	PMC4910734	6/2015	S174-PMC4910734	['as modeled infigure 5, the Intracellular damage occurs first in a localized area near the origination site of the endogenous Aldehydes, creating the selective Nutrient deficiencies and inactivating both large and small Molecules INVOLVED in antioxidant Defense mechanisms.']	[('SUPERFICIAL_RELATIONSHIP', 229)]	1	[('GO_0005622', 'intracellular anatomical structure', 27, 'intracellular'), ('CHEBI_17478', 'aldehyde', 125, 'aldehydes'), ('CHEBI_33284', 'nutrient', 159, 'nutrient'), ('CHEBI_36357', 'polyatomic entity', 219, 'molecules'), ('GO_0006952', 'defense response', 253, 'defense')]
S180-PMC4910734	PMC4910734	6/2015	S180-PMC4910734	['many of the environmental RISK FACTORS, such as air pollution, new industrial products, and Food flavorings, contain exogenous Aldehydes, which CAN accelerate a decline in the antioxidant Defense mechanisms.']	[('SUPERFICIAL_RELATIONSHIP', 26), ('INCOMPLETE_EVIDENCE', 144)]	2	[('CHEBI_33290', 'food', 92, 'food'), ('CHEBI_17478', 'aldehyde', 127, 'aldehydes'), ('GO_0006952', 'defense response', 188, 'defense')]
S11-PMC4921626	PMC4921626	6/2016	S11-PMC4921626	"[""id CAN have several adverse EFFECTS on children's health including impaired growth, poor Cognitive and Motor Development, lethargy, and alterations of Immune Defense mechanisms [1].""]"	[('INCOMPLETE_EVIDENCE', 3), ('SUPERFICIAL_RELATIONSHIP', 28)]	2	[('GO_0050890', 'cognition', 89, 'cognitive ...'), ('GO_0009653', 'anatomical structure morphogenesis', 103, 'motor development'), ('UBERON_0002405', 'immune system', 151, 'immune'), ('GO_0006952', 'defense response', 158, 'defense')]
S44-PMC4931906	PMC4931906	5/2016	S44-PMC4931906	['Nicotine triggers MOST known Human Toxin Defense mechanisms, for instance, including Bitter Taste receptors in the Mouth and Gut, Bitter Taste pathways in the Peripheral Nervous System, Xenobiotic-Sensing Nuclear receptors, Xenobiotic-Metabolizing enzymes, aversion Circuitry in the Central Nervous System and Conditioned Taste Avoidance (reviewed in ref.']	[('PROBABLE_UNDERSTANDING', 18)]	1	[('CHEBI_17790', 'methanol', 0, 'Nicotine'), ('NCBITaxon_9606', 'Homo sapiens', 29, 'human'), ('CHEBI_27026', 'toxin', 35, 'toxin'), ('GO_0006952', 'defense response', 41, 'defense'), ('GO_0050913', 'sensory perception of bitter taste', 85, 'bitter taste'), ('UBERON_0000165', 'mouth', 115, 'mouth'), ('UBERON_0001555', 'digestive tract', 125, 'gut'), ('GO_0050913', 'sensory perception of bitter taste', 130, 'bitter taste'), ('UBERON_0000010', 'peripheral nervous system', 159, 'peripheral nervous system'), ('CHEBI_35703', 'xenobiotic', 186, 'xenobiotic'), ('GO_0007414', 'axonal defasciculation', 186, 'xenobiotic-sensing'), ('GO_0005634', 'nucleus', 205, 'nuclear'), ('CHEBI_35703', 'xenobiotic', 224, 'xenobiotic'), ('GO_0007411', 'axon guidance', 224, 'xenobiotic-metabolizing'), ('UBERON_0024914', 'circuit part of central nervous system', 266, 'circuitry'), ('UBERON_0001017', 'central nervous system', 283, 'central nervous system'), ('GO_0008306', 'associative learning', 310, 'conditioned taste avoidance')]
S273-PMC4931906	PMC4931906	5/2016	S273-PMC4931906	['FURTHER RESEARCH SHOULD determine the extent to which hormone changes in Pregnancy activate Toxin avoidance and Defense mechanisms, and the extent to which such mechanisms DETER tobacco use.']	[('FUTURE_WORK', 0), ('FUTURE_WORK', 17), ('SUPERFICIAL_RELATIONSHIP', 172)]	3	[('GO_0007565', 'female pregnancy', 73, 'pregnancy'), ('CHEBI_27026', 'toxin', 92, 'toxin'), ('GO_0006952', 'defense response', 112, 'defense')]
S267-PMC4989298	PMC4989298	8/2016	S267-PMC4989298	['the Immune System of children, leading a “western” lifestyle were predominantly directed towards an allergic-type response because they did not contribute to Defence against infectious Agents and thus induced the maturation of a MAINLY T-Helper type 2 (th2) RATHER than T-helper type 1 (th1) Immune Response.']	[('PROBABLE_UNDERSTANDING', 229), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 258)]	2	[('UBERON_0002405', 'immune system', 4, 'immune system'), ('GO_0006952', 'defense response', 158, 'defence'), ('CHEBI_33250', 'atom', 185, 'agents'), ('CL_0000805', 'immature single positive thymocyte', 236, 'T ... helper'), ('CL_0000895', 'naive thymus-derived CD4-positive, alpha-beta T cell', 270, 'T'), ('GO_0006955', 'immune response', 292, 'immune response'), ('UBERON_0002405', 'immune system', 292, 'immune')]
S148-PMC4995781	PMC4995781	8/2016	S148-PMC4995781	['the overall EFFECT APPEARS TO BE aimed at ensuring Nutrient supply to nurture the fetus plus maternal Defence against excessive demand, reflecting the specifics of the drain particularly in Glucose and specific Fatty Acids (e.g.']	[('SUPERFICIAL_RELATIONSHIP', 12), ('ANOMALY_CURIOUS_FINDING', 19)]	2	[('CHEBI_33284', 'nutrient', 51, 'nutrient'), ('GO_0006952', 'defense response', 102, 'defence'), ('CHEBI_17234', 'glucose', 190, 'glucose'), ('CHEBI_35366', 'fatty acid', 211, 'fatty acids')]
S20-PMC4997411	PMC4997411	8/2016	S20-PMC4997411	['THEREFORE, it is NECESSARY to investigate the LINK between high fat nutrition and the fetal immature antioxidant Defense system, as well as to study their INFLUENCE on the Reproduction health of offspring.']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 17), ('SUPERFICIAL_RELATIONSHIP', 46), ('SUPERFICIAL_RELATIONSHIP', 155)]	4	[('GO_0006952', 'defense response', 113, 'defense'), ('GO_0000003', 'reproduction', 172, 'reproduction')]
S206-PMC4997411	PMC4997411	8/2016	S206-PMC4997411	['in THIS STUDY, a high fat maternal Nutrient supply would satisfy fetal Nutrient REQUIREMENTS, but results in a range of fetal maladaptations and MAY deteriorate the body’s antioxidant Defense system.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('IMPORTANT_CONSIDERATION', 80), ('INCOMPLETE_EVIDENCE', 145)]	3	[('CHEBI_33284', 'nutrient', 35, 'nutrient'), ('CHEBI_33284', 'nutrient', 71, 'nutrient'), ('GO_0006952', 'defense response', 184, 'defense')]
S27-PMC5041052	PMC5041052	8/2016	S27-PMC5041052	['IN ACCORDANCE WITH the dohad HYPOTHESIS [15], Embryo Defense STRATEGIES against in vitro stress exposures COULD AFFECT the Programming of Cell States and signaling Pathways, leading to aberrant responses to normal physiological signals, exhaustion of cell machinery, and long-term Metabolic phenotypes.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 29), ('FUTURE_WORK', 61), ('INCOMPLETE_EVIDENCE', 106), ('SUPERFICIAL_RELATIONSHIP', 112)]	5	[('UBERON_0000922', 'embryo', 46, 'embryo'), ('GO_0006952', 'defense response', 53, 'defense'), ('GO_0007565', 'female pregnancy', 123, 'programming'), ('GO_0007049', 'cell cycle', 138, 'cell states'), ('GO_0007567', 'parturition', 164, 'pathways'), ('GO_0008152', 'metabolic process', 281, 'metabolic')]
S139-PMC5084028	PMC5084028	10/2016	S139-PMC5084028	['Zinc itself has antioxidant capabilities and is an integral structural component of Superoxide dismutase, a first line Defense antioxidant [115] which has reduced activity in cell lines, Animal MODELS and Human studies of zinc deficiency [116,117,118,119,120].']	[('INCOMPLETE_EVIDENCE', 194)]	1	"[('CHEBI_27377', ""Unsym-bis(4'-chlorophenyl)ethylene"", 0, 'Zinc'), ('CHEBI_18421', 'superoxide', 84, 'superoxide'), ('GO_0006952', 'defense response', 119, 'defense'), ('NCBITaxon_33208', 'Metazoa', 187, 'animal'), ('NCBITaxon_9606', 'Homo sapiens', 205, 'human')]"
S46-PMC5110566	PMC5110566	11/2016	S46-PMC5110566	['dysfunction in the Brainstem Oxidative Metabolism, using the same experimental MODEL, were observed in Rats immediately after weaning ASSOCIATED to the increase in Ros Production, with a decrease in antioxidant Defense and redox status (ferreira et al.,2015,2016).']	[('INCOMPLETE_EVIDENCE', 79), ('SUPERFICIAL_RELATIONSHIP', 134)]	2	[('UBERON_0002298', 'brainstem', 19, 'brainstem'), ('GO_0045333', 'cellular respiration', 29, 'oxidative metabolism'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 103, 'rats'), ('CHEBI_8756', 'RNA (poly(A))', 164, 'ROS'), ('GO_0071605', 'monocyte chemotactic protein-1 production', 164, 'ROS production'), ('GO_0006952', 'defense response', 211, 'defense')]
S158-PMC5183755	PMC5183755	12/2016	S158-PMC5183755	['the exact mechanisms by which Nicotine exposure DRIVES acceleration in the methylation age of unborn babies are GENERALLY NOT WELL UNDERSTOOD, ALTHOUGH they MAY BE PLAUSIBLY ATTRIBUTED to cellular Defense exhausting [34].']	[('SUPERFICIAL_RELATIONSHIP', 48), ('FULL_UNKNOWN', 112), ('PROBABLE_UNDERSTANDING', 112), ('FUTURE_WORK', 126), ('ANOMALY_CURIOUS_FINDING', 143), ('INCOMPLETE_EVIDENCE', 157), ('INCOMPLETE_EVIDENCE', 164), ('SUPERFICIAL_RELATIONSHIP', 174)]	8	[('CHEBI_25501', 'neoxanthin', 30, 'nicotine'), ('GO_0006952', 'defense response', 197, 'defense')]
S336-PMC5371292	PMC5371292	3/2017	S336-PMC5371292	['an increase in hepcidin production, OFTEN RELATED to inflammation, is a Defense against bacterial infection[56,57].']	[('PROBABLE_UNDERSTANDING', 36), ('SUPERFICIAL_RELATIONSHIP', 42)]	2	[('GO_0006952', 'defense response', 72, 'defense')]
S45-PMC5485170	PMC5485170	3/2017	S45-PMC5485170	['the Human host further restricts the availability of iron by ensuring its tight binding to chaperone proteins (e.g., haemoglobin, Transferrin, ferritin, Lactoferrin), and by Modulating the abundance of these proteins as a Defence against Extracellular pathogens that could otherwise cause a rapidly fatal septicaemia (‘iron withholding HYPOTHESIS’).']	[('INCOMPLETE_EVIDENCE', 336)]	1	[('NCBITaxon_9606', 'Homo sapiens', 4, 'human'), ('PR_000016293', 'protein-glutamine gamma-glutamyltransferase 2', 130, 'transferrin'), ('PR_000002198', 'catenin beta-1', 153, 'lactoferrin'), ('GO_0065007', 'biological regulation', 174, 'modulating'), ('GO_0006952', 'defense response', 222, 'defence'), ('GO_0005576', 'extracellular region', 238, 'extracellular')]
S51-PMC5523023	PMC5523023	7/2017	S51-PMC5523023	['chronic inflammation decreases the capacity of endogenous antioxidant Defense mechanisms, which are NOT ABLE to compensate overproduction of Ros/Rns.']	[('DIFFICULT_TASK', 100)]	1	[('GO_0006952', 'defense response', 70, 'defense'), ('CHEBI_8756', 'RNA (poly(A))', 141, 'ROS'), ('GO_0016246', 'RNA interference', 145, 'RNS')]
S1-PMC555773	PMC555773	9/2004	S1-PMC555773	['RECENT STUDIES have also REVEALED a ROLE for No as Signaling Molecule in Plant, as it activates various Defense Genes and acts as developmental regulator.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 25), ('SUPERFICIAL_RELATIONSHIP', 36)]	3	[('CHEBI_16382', 'iodide', 45, 'NO'), ('CHEBI_62488', 'signalling molecule', 51, 'signaling molecule'), ('NCBITaxon_33208', 'Metazoa', 73, 'plant'), ('GO_0006952', 'defense response', 104, 'defense'), ('SO_0000704', 'gene', 112, 'genes')]
S27-PMC555773	PMC555773	9/2004	S27-PMC555773	['in addition, no activates the Expression of several Defense Genes (eg, pathogenesis-related Genes, Phenylalanine Ammonia-lyase , Chalcone Synthase ) and COULD play a ROLE in pathways leading to systemic acquired resistance [13].']	[('INCOMPLETE_EVIDENCE', 153), ('SUPERFICIAL_RELATIONSHIP', 166)]	2	[('GO_0010467', 'gene expression', 30, 'expression'), ('GO_0006952', 'defense response', 52, 'defense'), ('SO_0000704', 'gene', 60, 'genes'), ('SO_0000704', 'gene', 92, 'genes'), ('CHEBI_25973', 'phenylacetaldehydes', 99, 'phenylalanine ammonia'), ('CHEBI_27618', 'chalcone', 129, 'chalcone'), ('PR_000015699', 'alpha-2,8-sialyltransferase 8E', 138, 'synthase')]
S228-PMC5680205	PMC5680205	11/2017	S228-PMC5680205	['Zinc itself is capable of acting as an antioxidant but is also REQUIRED as a structural component of a number OF first line Defence antioxidant Molecules55,56.']	[('IMPORTANT_CONSIDERATION', 63), ('ANOMALY_CURIOUS_FINDING', 110)]	2	"[('CHEBI_27377', ""Unsym-bis(4'-chlorophenyl)ethylene"", 0, 'Zinc'), ('GO_0006952', 'defense response', 124, 'defence'), ('CHEBI_52435', 'propicillin(1-)', 144, 'molecules55')]"
S62-PMC5716389	PMC5716389	9/2017	S62-PMC5716389	['Innate Immunity is MOSTLY the first general line of Defense; the cell types INVOLVED are Macrophages, Neutrophils and Nk Cells [46].']	[('PROBABLE_UNDERSTANDING', 19), ('SUPERFICIAL_RELATIONSHIP', 76)]	2	[('GO_0045087', 'innate immune response', 0, 'Innate immunity'), ('GO_0006952', 'defense response', 52, 'defense'), ('CL_0000235', 'macrophage', 89, 'macrophages'), ('CL_0000775', 'neutrophil', 102, 'neutrophils'), ('CL_0000623', 'natural killer cell', 118, 'NK cells'), ('GO_0005634', 'nucleus', 118, 'NK')]
S459-PMC5941617	PMC5941617	5/2018	S459-PMC5941617	['it HAS BEEN SUGGESTED that early-Life Vitamin D deficiency MAY CONTRIBUTE to the pathogenesis of childhood-onset cd by determining inappropriate Immune Responses, abnormal Intestinal Mucosal integrity and impaired local Defence against Microbial agents [413].']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 59), ('SUPERFICIAL_RELATIONSHIP', 63)]	3	[('UBERON_0000104', 'life cycle', 33, 'life'), ('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('GO_0006955', 'immune response', 145, 'immune responses'), ('UBERON_0002405', 'immune system', 145, 'immune'), ('UBERON_0001262', 'wall of intestine', 172, 'intestinal mucosal'), ('GO_0006952', 'defense response', 220, 'defence'), ('NCBITaxon_10088', 'Mus <genus>', 236, 'microbial')]
